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ABSTRACT 
p90 and UHRF1, Two Novel Regulators of the p53 Signaling Pathway 
Chao Dai 
 
To ensure proper and differentiated regulation of stress response pathways, 
the p53 tumor suppressor calls for an intricate network of control of activation 
and fine tuning of transcription activity, which is offered largely through post-
translational modifications. Accumulating evidence supports the indispensability 
of acetylation in the activation of p53 function and indicates modulation of cell 
fate decision; however the underlying molecular mechanisms are not well 
understood and identification of the regulatory mechanisms controlling p53 
acetylation remains an important step in furthering the understanding of p53 
regulation in vivo. In this study we identify p90 and UHRF1 as two novel 
members of the p53 regulatory network upstream of TIP60-mediated p53 
acetylation.   
Through biochemical purification, p90 was identified as a unique regulator for 
p53. p90 (also called CCDC8, coiled-coil domain containing 8) interacts with p53 
both in vitro and in vivo. Depletion of p90 by RNAi has no obvious effect on p53 
stability or p53-mediated activation of p21, but specifically abrogates PUMA 
activation. Moreover, p90 also interacts with the TIP60 acetyltransferase and 
stimulates TIP60-dependent Lys120 acetylation of p53, therefore enhancing the 
apoptotic response of p53. These data reveal p90 as an upstream regulator of the 
Tip60-p53 interaction and demonstrate that p90 is specifically required for p53-
mediated apoptosis upon DNA damage. 
We also report that the epigenetic regulator UHRF1 (ubiquitin-like with PHD 
and RING finger domains 1) interacts with TIP60 and induces degradation-
independent ubiquitination of TIP60. Moreover, UHRF1 markedly suppresses the 
ability of TIP60 to acetylate p53. In contrast, RNAi-mediated inactivation of 
UHRF1 increases endogenous p53 acetylation and significantly augments p53-
mediated apoptosis.  To elucidate the mechanisms of this regulation, we found 
that the interaction between TIP60 and p53 is severely inhibited in the presence of 
UHRF1, suggesting that UHRF1 modulates TIP60-mediated functions in both 
K120 acetylation-dependent and -independent manners. Consistent with this 
notion, UHRF1 knockdown promotes activation of p21 and PUMA but not 
HDM2. These findings demonstrate that UHRF1 is a critical negative regulator of 
TIP60 and suggest that UHRF1-mediated effects on p53 may contribute, at least 
in part, to its role in tumorigenesis. 
This study provides insight for understanding the regulation of p53 acetylation 
and cell fate decision. Both p90 and UHRF1 are previously unidentified members 
of the p53 regulatory network. Although both function upstream of the TIP60-p53 
interplay, they act through distinct and opposing mechanisms to dynamically 
regulate TIP60-mediated effects on p53 in vivo.  
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1.1 p53 is a tumor suppressor 
p53, encoded by the TP53 gene, is often regarded as “guardian of the genome” 
because of its pivotal role in tumor suppression [1]. p53 was initially discovered 
independently by David Lane and Arnold Levine in 1979 as a simian virus 40 
(SV40) large T antigen interacting partner that migrates at 53 kDa on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) [2,3]. Early 
work revealing excessive p53 production in transformed and cancer cells and 
work demonstrating that p53 cooperates with the Ras oncoprotein to transform or 
immortalize cells led to the classification of p53 as an oncoprotein [4-7]. It was 
later found that the TP53 cDNA initially cloned from tumor cell mRNA was a 
dominant negative allele containing a valine (V) to alanine (A) mutation at codon 
135 that activates transforming properties. In 1989, work by the Oren group and 
Levine group showing that wild type p53 could suppress oncogene driven 
transformation and work by the Vogelstein group demonstrating frequent 
mutations of the TP53 gene in human colorectal carcinomas collectively 
characterized p53 as a tumor suppressor [8-10].   
Following these initial observations, TP53 mutations were reported in a wide 
spectrum of human cancers, with mutation rates ranging from ~10% in 
hematopoietic malignancies to ~50%-70% in ovarian, colorectal, lung, and head 
and neck malignancies [11]. Trp53 (encoding mouse p53) deficient mice are 
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susceptible to early onset spontaneous tumorigenesis [12], and germline mutation 
of p53 in humans which leaves only one functional allele of the TP53 gene is 
associated with the Li-Fraumeni syndrome characterized by a 25-fold increase in 
cancer susceptibility and early onset of a wide range of malignancies such as 
breast cancer, brain tumors, and soft tissue sarcomas [13,14]. It is now known that 
p53 mutations or perturbation of the p53 regulatory network exist in over half of 
all human cancer cases [15-17].  
 
1.2 p53 functions as a sequence-specific transcription factor 
The p53 protein comprises several domains: an amino (N-) terminal 
transactivation domain (TAD; consisting of two transactivation subdomains, 
TAD-I, residues 1-42, and TAD-II, residues 43-62) [18-20], a proline rich domain 
(PRD; residues 63-97), a central DNA binding core domain (DBD; residues 100-
300) [21,22], a tetramerization domain (TD; residues 307-355) [23,24], and a 
carboxyl (C-) terminal regulatory domain (CTD; residues 356-393) [25].  
Soon after its characterization as a bona fide tumor suppressor, p53 was 
identified to possess binding affinity, through its central domain, to specific DNA 
sequences termed “the p53 consensus binding site” or “the p53 response element” 
[26]. The consensus sequence consists of two 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ 
4 
 
decameric palindromes called “p53 binding half-sites” separated by 0-13 
basepairs [26].  
The presence of p53 response elements in the regulatory regions (promoters, 
introns, and upstream sequences) of genes predicts transcription regulation by p53. 
A combination of gene expression microarrays, chromatin-immunoprecipitation-
based microarrays (ChIP-chip) and ChIP sequencing analysis have to date 
identified at least 500 p53 binding loci throughout the human genome [27-30]. At 
least 100 genes have been identified to possess p53 response elements and are 
experimentally validated as p53 target genes [31,32].  
DNA sequencing of tumor samples bearing mutant p53 revealed that the vast 
majority of p53 mutations are missense mutations within the DNA binding 
domain, resulting in mutant p53 proteins with altered conformation and attenuated 
sequence-specific binding to DNA [33]. The significance of p53 mutations in 
tumorigenesis is 3-fold: (i) they abolish wild type p53 function, (ii) they create 
dominant negative activity through tetramer formation with wild type p53, and (iii) 
they convey “oncogenic” function through the selective growth advantages of 
cells with the mutations, the transactivation of new target genes or via 




1.3 p53 centrally coordinates cellular responses to a wide range of stresses 
p53 exerts tumor suppressive capacities by centrally coordinating a regulatory 
circuit that monitors and responds to a variety of stress signals. Under 
homeostasis, both p53 abundance and p53 transcription activity is kept low by its 
primary negative regulators Human Double Minute 2 (HDM2, mouse ortholog is 
Mdm2) and Human Double Minute X (HDMX, mouse ortholog is MdmX).  In 
the event of genotoxic stresses such as DNA damage, abnormal oncogene 
activation, telomere erosion, hypoxia etc, p53 is rapidly stabilized and activated to 
transcribe target genes that mediate cell cycle arrest, apoptosis, DNA repair, 
senescence, energy metabolism, or autophagy. Through executing and balancing 
these cellular responses, p53 ultimately protects cellular and genomic stability, 
preventing the propagation of genetic lesions and tumor formation.   
A multitude of chemo-reagents converge onto the activation of p53. The 
cytotoxic agent etoposide forms a ternary complex with DNA and the 
topoisomerase II enzyme, thus preventing re-ligation of the DNA strand and 
causing DNA strand breaks in cancerous cells that undergo rapid DNA replication 
and cell division [35]. The anthracyclines (doxorubicin, daunorubicin, and their 
derivatives) work by intercalating DNA as well as undergoing redox reactions 
that generate reactive oxygen species (ROS) [36]. DNA strand breaks are 
recognized by the MRN complex (consisting of three proteins Mre11, RAD50, 
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and NBS1) which in turn activates ATM-CHK1 or ATM-CHK2 kinase cascades 
that transmit this information to p53 through phosphorylating both p53 and 
HDM2, ultimately inhibiting their association and stabilizing p53 [37]. Reagents 
that disrupt rRNA biogenesis, such as actinomycin D, increase ribosomal stress 
and release ribosomal proteins from the nucleoli, which in turn bind to HDM2 and 
result in p53 stabilization [38]. The uracil analogue 5-fluorouracil (5-FU) 
antimetabolite functions through misincorporation into nascent RNA and 
irreversibly blocking thymidylate synthase, causing dTMP depletion in rapidly 
dividing cells [39], as well as triggering a ribosomal stress response that releases 
ribosomal proteins to activate p53 by ablating the HDM2-p53 feedback loop [40]. 
Although the p53 effects are predominantly exerted through its transcription 
activation of target genes, our knowledge of p53 functions have been expanded 
into transcription repression [41], regulation of translation [42] and homologous 
recombination [43], and the induction of a transcription-independent apoptotic 
response [44]. 
 
1.4 p53 and the “big three”: growth arrest, apoptosis and senescence 
Growth arrest, apoptosis, and senescence are the most well characterized 
cellular responses following p53 activation and thought of as major mediators of 
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the tumor suppressive function of p53. The ability of p53 to remove damaged 
cells through apoptosis is a more evolutionarily conserved function: in lower 
eukaryotes, including D. melanogaster and C. elegans, p53 is critical for 
eliminating damaged cells to preserve germline and tissue integrity [45]. In higher 
eukaryotes, genotoxic stresses activate p53, leading to cell cycle pauses allowing 
time for damage repair or the irreversible cellular senescence or apoptosis in the 
event of prolonged damage as safeguards against neoplasia [31].   
Here I will briefly revisit the means by which p53 regulates each of these 
pathways, and discuss their roles in tumor suppression.   
1.4.1 Growth arrest 
Cell cycle checkpoint is a common theme of regulation in eukaryotes to 
ensure fidelity of DNA replication and mitosis, thus protecting from propagation 
of genetic lesions and progressive accumulation of genomic changes that 
eventually leads to neoplastic transformation. Halting the cell cycle at checkpoints 
presumably permits repair of damage before the cell reinitiates DNA replication 
(G1 arrest) or enters mitosis (G2 arrest).  
The first line of evidence suggesting p53 control of cell cycle progression 
comes from the work from Kastan and colleagues demonstrating that ataxia 
telangiectasia mutated (ATM), p53 and GADD45 comprise a signal transduction 
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pathway that controls the mitotic checkpoint upon DNA damage [46]. Soon 
afterwards, p53 was shown to be required for G1 checkpoint arrest following 
DNA damage, primarily through transcription activation of one of the best 
characterized p53 target genes CDKN1A encoding p21
CIP1/WAF1
, a cyclin-
dependent kinase (CDK) inhibitor [47,48]. Elevated p21, through binding to and 
inactivating cyclin/CDK complexes required for the G1/S transition, arrests cells 
in the G1 phase to allow time for DNA damage repair.  
Mouse embryonic fibroblasts (MEFs) derived from mice lacking p21 are 
almost entirely deficient in G1 arrest following DNA damage, underlying the 




 mice are not susceptible to early onset of spontaneous tumor 
development [49]. Nevertheless, loss of p21 promotes tumor initiation, 
progression or metastasis in some mouse tumor models driven by carcinogens, 
activated oncogene or γ-irradiation [50,51], suggesting that p21 deficiency 
promotes tumorigenesis in certain settings.  
1.4.2 Apoptosis 
The finding of p53 regulation of apoptosis comes from work by Oren and 
colleagues utilizing a temperature-sensitive p53 mutant that behaved like wild 
type p53 at the permissive temperature. Re-introduction of p53 into p53-deficient 
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myeloid leukemia cells potently induced apoptosis that could be counteracted by a 
pro-survival cytokine [52].   
It is now known that at least three apoptotic pathways exist (the mitochondrial 
pathway, the death receptor pathway, and the endoplasmic reticulum pathway) 
and they cross-communicate with each other and converge to a common 
downstream caspase activation that eventually leads to programmed cell death 
[53].  
p53 can transactivate a wide array of downstream death effectors including 
the pro-apoptotic Bcl-2 family members Bax [54], Bid [55], PUMA [56] and 
NOXA [57] involved in the mitochondrial apoptotic pathway, Killer/Dr5 and Fas 
(also called CD95 and Apo-1) of the death-receptor pathway [58-61], and Scotin 
of the endoplasmic reticulum pathway [62]. In addition to transactivating death 
effectors, p53 can mediate transcription repression of anti-apoptotic proteins (Bcl-
2, Bcl-XL, and survivin) [63-65], or cytoplasmic p53 can translocate to the 
mitochondria and directly interact with pro- and anti-apoptotic Bcl-2 family 
members to induce mitochondrial outer membrane permeabilization (MOMP) 
[66-71].  
Despite the many p53-activated death effectors and the transcription-
independent apoptotic function of cytoplasmic p53, p53-induced apoptosis in vivo 
is mediated predominantly by PUMA and to a lesser extent by NOXA [57,72-75], 
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because Bbc3 (puma) knockout mice recapitulates nearly all apoptotic 
deficiencies in Trp53 knockout  mice, although in a tissue specific manner further 
loss of Pmaip1 (noxa) was required for the complete abolishment of apoptosis 
following whole body gamma-irradiation [75].  
p53 mediated apoptosis undoubtedly plays an important role in suppressing 
tumor growth and progression in response to oncogenic events or DNA damage. 
Using a brain cancer mouse model in which the pRB tumor suppressor is 
perturbed, Dyke and colleagues showed the first evidence that apoptosis 
contributes to p53 tumor suppression function in vivo: tumors develop 
aggressively in the absence of p53 but grow slowly in the presence of p53, and 
that this is attributed to high levels of p53-dependent apoptosis [76]. In addition, 
in Eµ-Myc transgenic mice, a model for B-cell lymphoma, disruption of apoptosis 
downstream of p53 through Bcl-2 or dominant negative caspase 9 expression, 
recapitulates the tumor growth advantage observed for loss of p53 [77]. 
Furthermore, lymphoma development driven by c-Myc or low dose γ-irradiation 
is significantly accelerated by loss of puma and/or noxa [78-80].  
1.4.3 Senescence 
Cellular senescence is the process of irreversible cell-cycle arrest in spite of 
mitogenic signals, and was first described almost fifty years ago by Hayflick and 
colleagues when they showed that normal cells had a finite proliferative capacity 
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in culture [81].  Senescent cells manifest phenotypic changes including a 
flattened/enlarged morphology, increased adherence, and the expression of 
senescence-associated β-galactosidase (SA-β-GAL), the staining of which is a 
common and reliable method for detection of senescence [82,83]. Senescent cells 
also acquire an altered gene expression profile, including upregulation of 
inflammatory cytokines and other immune modulators [84].  
Although replicative senescence is triggered by telomere erosion, premature 
senescence can also be acutely achieved through oncogene activation, oxidative 
stress, DNA damage and treatment with anticancer drugs [85-87], all of which 
seemingly converge upon the activation of the DNA damage response (DDR).  
Both telomere- and damage-initiated cellular senescence depend strongly on 
p53 mediated induction of the pleiotropic CDK inhibitor p21. In many cases, this 
is followed by a delayed stable activation of p16
Ink4A
 (encoded by CDKN2a) CDK 
inhibitor [88], which itself is a tumor suppressor frequently mutated in cancer 
[89,90]. It is believed that p53 acts to initiate senescence through the induction of 
p21, while the subsequent increase in p16 level then acts to maintain senescence.  
The fact that cancer cells are immortal and can proliferate indefinitely 
suggests that cellular senescence needs to be bypassed at some point prior to 
malignant transformation. One such example would be the common benign 
human tumor melanocytic naevi (moles), which frequently possess oncogenic 
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mutations but typically remain in a growth arrested state for decades and only 
rarely progress to malignant melanomas [91]. Indeed, senescence markers are 
expressed by nevi in vivo [91], demonstrating that cellular senescence efficiently 
suppresses malignant transformation of benign tumors.  
Studies with oncogene driven tumor mouse models support the role of p53-
mediated cellular senescence in suppressing tumor in vivo. Expression of 
oncogenic Eµ-N-Ras in p53 knockout mice readily drives aggressive T cell 
lymphomas, whereas in the presence of wild type p53 Eµ-N-Ras transgenic mice 
developed nonlymphoid neoplasia with prevalent signs of senescence [92]. An 
oncogenic K-Ras
G12V
 transgenic mouse model also demonstrates senescence in 
the early stages of lung and pancreatic tumors [93].  
Importantly, reactivation of p53 in p53-deficient liver carcinoma induced the 
cellular senescence program, in turn triggering tumor clearance in vivo through 
the innate immune system [94], highlighting the potential of tailored pro-
senescence therapies in cancer treatment.  
1.4.4 Tumor suppression: the “big three” and beyond 
Over the past 30 years of p53 research, the tumor suppressive capacity of p53 
cell-cycle arrest, apoptosis, and senescence targets have been rigorously tested 
using target gene knockout mouse models, and numerous studies have 
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demonstrated the importance of several key targets in suppressing tumor in the 
context of oncogene activation, tumor suppressor deficiency, irradiation, and 
DNA damage. However, increasing evidence suggests that p53-mediated tumor 
suppression is more complex than just the “big three”.  
A number of knockout mice lacking single p53 target genes have been 
generated, and none of these could recapitulate the dramatic and completely 
penetrant phenotype of spontaneous tumor predisposition observed in Trp53 null 















mice, which again were not prone 
to spontaneous early onset of tumorigenesis [78,96,97].  
A recent p53
3KR/3KR 
knockin mouse generated by the Gu team, in which three 
lysine (K) acetylation sites (K117, K161, and K162; human counterparts are 
K120 and K164) were collectively mutated to the non-acetylable arginine (R) 
residue, was still resistant to spontaneous tumorigenesis despite loss of DNA-
damage induced growth arrest, apoptosis, and senescence [98], suggesting that 
loss of all three functions is insufficient for abrogating p53 tumor suppression in 
vivo.  Strikingly, p53
3KR/3KR 
retains regulation of non-conventional target genes 
involved in energy metabolism (upregulation of GLS2, encoding a mitochondrial 
glutaminase that modulates mitochondrial respiration and ATP generation; 
downregulation of GLUT3, encoding a glucose transporter) and reactive oxygen 
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species production (upregulation of TIGAR, encoding a a fructose bisphosphatase 
that downregulates glycolysis by reducing cellular levels of fructose-2, 6,-
bisphosphate), implying that these non-canonical p53 functions may be more 
relevant to suppression of early onset tumorigenesis in vivo.  
Interestingly, loss of growth arrest, apoptosis, and senescence seems to confer 
a certain degree of genome instability. Indeed, in the p53
3KR/3KR 
background, de 
novo mutation of Trp53
3KR 
gene is observed in several animals, contributing to 
latent spontaneous tumorigenesis [98].  Similarly, taking advantage of the 
hypomorphic p53
R172P
 mutant that delays spontaneous tumor onset due to 





 mice display accelerated tumor onset compared 
to Trp53
R172P/R172P
 mice due to genome instability as demonstrated by aneuploidy 





It is probable that different p53-dependent response pathways are 
differentially required for tumor suppression under different biological settings or 
tumor types, and the composite loss of several effector pathways (coordination of 
cell cycle arrest, apoptosis, senescence, DNA repair, energy metabolism, etc.) 
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collectively accounts for the high penetrance and early onset of tumors when p53 
is mutated in mice [12]  and in humans (Li-Fraumeni syndrome) [14].  
For instance, in an unchallenged state, cell cycle arrest, apoptosis and 
senescence may keep damaged cells in check; however these may not be the rate 
limiting step in protecting from tumor formation. Instead, loss of apoptosis and 
temporary or permanent growth arrest allows proliferation of damaged cells and 
accumulation of genome instability, eventually leading to surpassing certain 
thresholds in energy metabolism, allowing for selective growth advantage of 
cancer cells.  
Importantly, unlike laboratory animals, humans are frequently challenged by 
environmental insults, increasing chances for acquiring carcinogen or oncogene-
driven mutation. Under these stress conditions, cell cycle, apoptosis, and 




1.5 Regulation of p53 function 
In order to coordinate a wide variety of cellular processes, p53 demands a 
refined and complicated regulatory network consisting of many positive and 
negative regulators. At homeostasis, the steady state level of p53 is kept low and 
p53 function is repressed mainly by the negative regulators HDM2 and HDMX. 
Under stress conditions, however, p53 is stabilized, translocated to the nucleus, 
released from repression, and its transcription activity is further activated in a 
promoter-specific manner.  
Significantly, covalent post-translational modifications play a pivotal role in 
the regulation of p53 under homeostasis and every aspect of the stress induced 
p53 response. p53 harbors many conserved amino acid residues that can be 
regulated by a multitude of post-translational modifications, including  
ubiquitination, phosphorylation, acetylation, methylation, sumoylation and 
neddylation (Fig. 1). Interestingly, a single enzyme may target several p53 sites 
for modification, and a single site may be targeted for multiple modifications. 
Many modifications display dramatic regulatory effects on p53 function as 
demonstrated in various in vitro and cell culture based studies, however 
transgenic mice expressing mutant p53 deficient in a single residue modification 




Here I will revisit some of the most important modes of regulation of p53 
stability, localization, DNA binding, cofactor recruitment and promoter-specific 
transcription activity, highlighting recent advances in our understanding of post-
translational modifications with key roles in modulating these aspects of p53 
regulation, their regulatory effects in vivo, and how deregulated p53 modifications 




Figure 1. Overview of p53 domain structure and post-translational 
modifications 
The major sites for p53 phosphorylation, ubiquitination, neddylation, sumoylation, 
acetylation and methylation are plotted. The enzymes responsible for each type of 
modification are shown on the right. Abbreviations: TAD, transactivation domain; 
PRD, proline rich domain; DBD, DNA-binding domain; TD, tetramerization 






1.5.1 Regulation of p53 stability 
The cellular protein stability of p53 is tightly controlled: p53 has a very short 
half-life in normal unstressed cells, ranging from 5-30 min [100], and the rapid 
stabilization of p53 following stress stimuli allows for exertion of diverse 
response pathways, such as the halter of cell cycle, the activation of the DNA 
damage repair response, and the induction of the apoptotic response, to combat 
theses stresses and protect cellular and genomic stability. The tight control of p53 
stability is made possible by the ubiquitin-dependent proteasome degradation 
pathway, with HDM2 being the chief mediator of p53 ubiquitination and 
degradation.  
1.5.1.1 Ubiquitination overview 
Ubiquitination refers to the covalent conjugation of one or more ~8 kDa 
ubiquitin molecules to a protein substrate, and requires the consecutive function 
of three enzymes. The E1 ubiquitin-activating enzyme links the C-terminal 
glycine of the ubiquitin molecule to its own active site cysteine through the 
formation of a thioester bond;  the ubiquitin molecule is then transferred to the 
active site cysteine of the E2 ubiquitin-conjugating enzyme; and finally an E3 
ubiquitin-ligating enzyme transfers the ubiquitin molecule to the protein 
susbstrate and directing it to rapid degradation by the 26S proteasome [101].  
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E1 and E2 enzymes have low substrate specificity: a single E1 can bind to 
dozens of E2s, and a single E2 can bind to hundreds of E3s in a hierarchical way. 
Unlike E1 and E2, the E3 ubiquitin ligase displays high target specificity, usually 
through a specific substrate recognition domain or through other cofactors in the 
case of multi-subunit E3 ubiquitin complexes.  
E3 ligases can be divided into two types: those that harbor a Really Interesting 
New Gene (RING) domain and those with a Homologous to the E6-AP Carboxyl 
Terminus (HECT) domain [102].  
1.5.1.2 p53 ubiquitination by HDM2 
HDM2 is the pivotal E3 ubiquitin ligase and negative regulator of p53 
[103,104]. HDM2 targets six p53 lysine (K) residues within the C-terminal 
regulatory domain (K370, K372, K373, K381, K382, and K386; Fig. 2), promotes 
p53 degradation by its E3 ubiquitin ligase function and ultimately inhibits p53 
transcription activity.  p53 is poly-ubiquitinated by high levels of HDM2 and 
mono-ubiquitinated by low levels of HDM2 [105]. HDM2-mediated suppression 
of p53 is 2-fold: (i) as an E3 ubiquitin ligase it targets p53 for ubiquitin-dependent 
proteasomal degradation and (ii) it inhibits p53 transcriptional activation by 




Importantly, the gene encoding HDM2 is a p53 transcription target, therefore 
the stress-induced increase in p53 levels leads to the expression of its own 
negative regulator HDM2, which in turn downregulates p53, creating an 
autoregulatory feedback loop [107]. The stabilization and activation of p53 go 
hand in hand with the inhibition of HDM2 E3 ubiquitin ligase function [108,109]. 
The p53/HDM2 feedback loop is regulated by multiple factors including the 
Alternate Reading Frame of the INK4a/ARF locus (ARF) tumor suppressor [110], 
the E3-ligase activity-lacking HDM2 homolog HDMX (also known as HDM4) 
[106] , the deubiquitinating enzyme ubiquitin specific protease 7 (USP7, also 
known as herpesvirus associated ubiquitin specific protease (HAUSP)) [111], and 
post-translational modifications of HDM2 such as phosphorylation and 
acetylation [112-114].  
The critical role for HDM2 suppression of p53 is best illustrated by the 
overactivation of p53 in mdm2 null mice leading to embryonic lethality, which 
can be rescued by the loss of p53 [115]. Furthermore, mice expressing a cysteine 
(C) 462A mutated version of mdm2 (equivalent to C464A in HDM2), which loses 
its E3 ligase activity but retains p53 binding capacity, die during embryogenesis 
but can be rescued by the loss of p53 [116], demonstrating that the E3 ligase 




1.5.1.3 p53 ubiquitination by HDM2-independent E3 ubiquitin ligases 
Despite the elevated p53 level and the spontaneous activation of p53 function 
in mdm2 null mice [117], supporting that HDM2 is the principal endogenous E3 
ubiquitin ligase targeting p53 with high specificity [118-120], p53 still undergoes 
degradation in the absence of mdm2 [117], suggesting the existence of HDM2-
independent degradation pathways.  
Indeed, several other E3 ligases have been shown to regulate p53 degradation 
and localization independent of HDM2. In cell culture, the RING domain 
containing p53-Induced protein with a RING-H2 domain (PIRH2) [121], 
Constitutively Photomorphogenic 1 (COP1) [122], Carboxy terminus of Hsp70p-
Interacting Protein (CHIP) [123], Caspase 8/10-Associated RING Proteins 
(CARPs) and SYNOVIOLIN [124,125], the HECT domain containing ARF-
Binding Protein 1 (ARF-BP1) [126] as well as Ubiquitin-Conjugating enzyme 13 
(UBC13) (containing neither domain) [127] poly-ubiquitinate p53 and target it for 
proteolysis. Whether these E3 ligases regulate p53 stability in vivo needs further 
genetic validation.  
Recent studies also support the existence of E4 ubiquitin ligases that 
specifically target mono-ubiquitinated p53 in the cytosol for homeostatic 
proteolytic degradation [128], possibly antagonizing the transcription-independent 
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apoptotic functions of cytosolic p53, which requires mono-ubiquitinated p53 in 
the mitochondria. 
The presence of multiple ubiquitin ligases that control p53 stability suggests a 
“fail-proof” redundancy in negative regulation. The capacity of these ligases to 
repress p53 function predicts that these p53-specific E3 ubiquitin ligases could be 
oncogenes. Indeed PIRH2, COP1 and WWP1 are amplified or overexpressed in 
certain cancers [129-131].  
1.5.1.4 p53 deubiquitination by USP7  
The ubiquitination of p53 is counteracted mainly by the USP7 
deubiquitinating enzyme. USP7 deubiquitinates p53, auto-ubiquitinated HDM2 
and ubiquitinated HDMX [132], and changes in USP7 levels produce non-linear 
effects on the p53-HDM2/HDMX pathway, therefore USP7 plays a dynamic role 
in tumorigenesis. 
 Moderate down regulation of USP7 preferably stabilizes HDM2, therefore 
leading to p53 destabilization and favors cell proliferation [133]. These data lend 
support to the finding in a study of patient samples of Non-small Cell Lung 
Cancer (NSCLC) that nearly 50% of NSCLC samples with wild-type p53 display 
reduced USP7 mRNA expression [134]. In contrast, complete loss of USP7 
function through a robust small interfering (si)RNA knockdown or knockout of 
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the usp7 gene destabilizes HDM2 and HDMX, therefore stabilizing p53 and 
would inhibit tumor growth [132]. This is consistent with the observation that no 
USP7 mutation was identified in the TP53
+/+
 NSCLC samples [134].  
Inhibition of USP7, therefore, presents a promising therapeutic approach for 
treating cancers that retain wild-type p53. Indeed, a small molecule inhibitor 
HBX41108 identified for USP7 by high-throughput screening stabilizes p53 in 
tissue culture and inhibits tumor cell growth [135],  warranting further studies to 
confirm the anti-tumor effect in vivo.  
1.5.2 Regulation of p53 localization  
In normal cells under homeostasis, p53 is shuttled between the nucleus and 
the cytoplasm [136]. In response to stress, however, p53 is rapidly translocated to 
the nucleus to exert its biological function as a transcription factor. The recent 
discovery of transcription-independent functions of p53 in the cytoplasm, 
including direct activation of apoptosis at the mitochondria and inhibition of 
autophagy, further underscore the importance of regulation of p53 localization 
[137-139]. Indeed, interference with p53 localization has detrimental effects in 
vivo: constitutive cytoplasmic localization of p53 has been linked to poor 
response to chemotherapy, tumor metastasis and poor prognosis [140-142]. 
1.5.2.1  Cytoplasmic targeting of p53 by ubiquitination 
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p53 ubiquitination not only targets it for proteasomal degradation, but also 
plays a key role in regulating the cellular localization of p53 (Fig. 2). p53 is 
polyubiquitinated when HDM2 levels are high and monoubiquitinated when 
HDM2 levels are low [105]. Poly-ubiquitination primarily targets p53 for 
proteasomal degradation, while mono-ubiquitination facilitates p53 cytoplasmic 
translocation through exposing a C-terminal nuclear export signal and promoting 
dissociation from HDM2 [103,143,144].  
Several other E3 ubiquitin ligases also preferentially target p53 for nuclear 
export independent of HDM2. WW domain-containing Protein 1 (WWP1) 
mediates p53 ubiquitination and, unlike HDM2, stabilizes p53 at the protein level 
and causes cytoplasimc accumulation of p53 [145]. Male-Specific Lethal-2 
(MSL2) also promotes p53 ubiquitination but does not regulate p53 protein level; 
instead it preferentially targets p53 for nuclear export [146].  
1.5.2.2 Nuclear import of p53 through deubiquitination by USP10  
Another member of the large deubiquitinase (DUB) family [147], USP10, has 
been shown to remove ubiquitin chains from p53. However, unlike USP7, USP10 
does not deubiquitinate HDM2 or HDMX. Rather, USP10 reverses HDM2-
induced p53 nuclear export, thereby recycling cytoplasmic p53 back to the 
nucleus [148]. Thus, although both USP7 and USP10 target p53 for 
deubiquitination, they function in different compartments: USP7 deubiquitinates 
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and stabilizes p53 primarily in the nucleus [111], whereas USP10 largely 
deubiquitinates cytoplasmic p53 during homeostasis, although it retains 
deubiquitinase activity upon translocation to the nucleus following DNA damage 
[148]. 
Using human Renal Cell Carcinoma (RCC) cell lines, Yuan and colleagues 
showed that USP10 is capable of stabilizing both wild-type and mutant p53; 
therefore USP10 might have different roles in tumorigenesis depending on the 
p53 status [148]. In RCC cell lines that retain wild-type p53, USP10 behaves like 
a tumor suppressor and upregulation of USP10 is favorable for repression of 
cancer growth. In RCC cell lines that have mutant p53, USP10 promotes cancer 
cell proliferation, and downregulation of USP10 would be beneficial for the 
inhibition of cancer growth. usp10 knockout mice studies would facilitate our 
understanding of the physiological role of USP10 in tumorigenesis. It is 
perceivable that discovery of USP10-activating or -inhibiting drugs would offer 




Figure 2. Regulation of p53 stability and localization by ubiquitination  
Nuclear p53 is targeted by HDM2 for monoubiquitination promoting cytoplasmic 
translocalization or polyubiquitination promoting proteosomal degradation. The 
abundance of HDM2 and HDMX are also regulated by ubiquitination and 
deubiquitination. USP7 stabilizes p53, HDM2, and HDMX through 
deubiquitination. In the cytoplasm, USP10 deubiquitinates monoubiquitinated p53, 
reversing nuclear export and recycling p53 into the nucleus. Monoubiquitinated 
p53 in the cytoplasm can possibly be further ubiquitinated by E4 ubiquitin ligases 
and targeted for degradation. Cytoplasmic p53 also has transcription-independent 
roles in activating apoptosis through permeabilization of the mitochondrial outer 
membrane and the inhibition of autophagy through mechanisms yet to be 






1.5.3 p53 repression on promoters by HDM2 and HDMX 
It was originally believed that p53 exists in a DNA-free form until cells 
encounter stress stimuli, which in turn stabilizes and activates sequence-specific 
DNA binding. However, increasing evidence now supports p53 basal binding to 
DNA in a non sequence-specific manner, and the presence of p53 repressors at 
target gene promoters prevent transcription activation until a stress stimuli occurs.  
1.5.3.1 p53 is bound to DNA at homeostasis   
Early studies focusing on the sequence specific DNA binding capacity of p53, 
often utilizing in vitro assays such as Electrophoretic Mobility Shift Assay 
(EMSA), led to the presumption that p53 exists in a DNA-free form under 
homeostasis and that only stress-activated p53 could bind to DNA.  DNA binding 
was also thought to be mediated exclusively by the p53 central core domain and 
requires stringent conformity to the consensus p53 response element. However 
global Chromatin immunoprecipitation (ChIP) and microarray analysis of p53 
binding to genomic DNA reveal considerable divergence from the consensus p53 
binding response element [29,149]. Instead, the majority of p53-binding events in 
vivo were found at non sequence-specific regions. 
It is now understood that both the p53 central core domain and the C-terminal 
regulatory domain possess DNA binding capacities [150,151], with the former 
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providing primarily sequence-specific DNA binding and the latter recognizing 
DNA structure and topology [150,152], thereby enabling DNA binding within the 
vicinity of canonical p53 binding sites and providing a basis for sliding and 
searching for specific sequences.  
Additionally, although promoter-binding of p53 is increased in response to 
genotoxic stress, quantitative ChIP assays reveal disproportionality to the fold 
induction of target gene mRNA; instead a portion of p53 is bound to target gene 
promoters in the absence of stress, and genotoxic stresses further enhances 
promoter binding [153]. These studies support a model in which p53 is bound to 
DNA but under constant repression.   
1.5.3.2  Repression of p53 at promoters by HDM2/HDMX 
Both HDM2 and HDMX interact directly with p53 and are recruited to p53 
response elements in a p53-dependent manner. HDM2, HDMX and p53 form a 
protein complex on target gene promoters and repress p53 function by preventing 
access to the general transcriptional machinery [154,155].  
The repression of p53 by HDM2 and HDMX is non-overlapping, because 
neither regulator can compensate for the embryonic lethality caused by the loss of 
the other [33]. The importance of HDM2 and HDMX in repressing p53 tumor 
suppressor function is further supported by the prevalence (around 1/3 of human 
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tumors) of HDM2 or HDMX gene amplification or overexpression in human 
tumors retaining wild-type p53 [33,156].  
1.5.3.3 De-repression of p53 is required for transcription activation 
While DNA binding alone may be sufficient for p53 to maintain basal level 
transcription of p53 negative regulators such as HDM2 and Pirh2 [106], in order 
to induce a stress response through transactivating distinct subsets of target genes 
p53 must first be released from HDM2/HDMX mediated repression. The 
necessity for disrupting HDM2 mediated repression is highlighted by the Nutlin-
3A small molecule HDM2 antagonist, currently in phase I clinical trial, that is 
sufficient to restore p53 transcription activity in cells with a wild type TP53 gene 
[157]. 
De-repression of p53 from HDM2 and HDMX can be achieved through 
several mechanisms. Post translational modifications on certain p53 residues 
facilitate the dissociation of p53 from HDM2 (discussed in detail in Chapter 
1.5.4). In response to DNA damage, HDM2 and HDMX also undergo a number 
of post-translational modifications that either decrease protein stability or disrupt 
interaction with p53 [112-114,158-160]. One such example is the ATM-
dependent phosphorylation of HDM2 and HDMX, which reduces their affinity for 
the USP7 deubiquitinase and therefore accelerates HDM2 and HDMX 





directly interacts with the central region of HDM2, thereby antagonizing its 
activity toward p53 [110]. Several nucleolar or ribosomal proteins also interact 
directly with HDM2 and prevent its negative regulation of p53 [38,161,162]. 
1.5.4 Regulation of p53 transcription activity by post-translational 
modifications 
p53 is subject to a diverse and complex array of post-translational 
modifications that influence its transcription activity at specific target gene 
promoters.  The most commonly reported post-translational modifications 
affecting p53 transcription activity include phosphosphorylation of serines and/or 
threonines and acetylation, sumoylation, neddylation and methylation of lysine 
residues (Fig. 1). The presence of multiple p53 residues targeted by a single 
enzyme and multiple modification possibilities on C-terminal lysines allows for a 
multitude of combinations of post translational modifications that can be 
conferred on the p53 protein. These serve as a “histone-like” code to dictate 
correct and differentiated activation of certain sets of downstream targets 
involving different cellular responses.  
1.5.4.1 Phosphorylation 
Human p53 harbors an array of serine (S)/threonine (T) phosphorylation sites 
that span the entire protein but are concentrated in the N-terminal transactivation 
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domain and the C-terminal regulatory domain (Fig. 1). The majority of these sites 
are rapidly phosphorylated following cellular stress, although a few (e.g. T55 and 
S376) are constitutively phosphorylated in unstressed cells and dephosphorylated 
following stress [163,164]. p53 phosphorylation at the N terminus shows 
significant redundancy; a single site can be phosphorylated by multiple kinases 
and a single kinase can phosphorylate multiple sites [106].  
1.5.4.1a Phorphorylation at Ser15/Ser20 
The most extensively studied N-terminal p53 phosphorylation sites are S15 
and S20 (S18 and S23 in mice). S15/S20 phosphorylation reduces p53 affinity for 
its primary negative regulator HDM2, and promotes the recruitment of 
transcriptional co-activators p300 and CBP on p53 target gene promoters [33]. 
Studies with mice containing single and double S to alanine (A) mutations reveal 
a certain level of redundancy in the physiological importance of these two 
phosphorylation sites. Although the individual mutations in gene knock-in 
experiments in mice only marginally change p53 stability and transactivation 
activity, the mice bearing p53 with both S15A and S20A mutations display a 
more severe phenotype including tissue-specific deficiency in pro-apoptotic 
capacity, mildly compromised replicative senescence and a latent development of 
a spectrum of tumors [165].  
1.5.4.1b Phosphorylation at Ser46 
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S46 phosphorylation has recently attracted much attention. Phosphorylation of 
S46 is critical for p53-mediated induction of pro-apoptotic genes such as p53-
regulated Apoptosis-Inducing Protein 1 (p53AIP1) but is not required for the 
induction of cell cycle arrest targets [166,167]. Indeed, the resistance of a human 
oral squamous cell carcinoma cell line HSC-3 to p53 is attributed to deficiency in 
S46 phosphorylation, and the introduction of the exogenous phospho-mimic 
p53S46D (aspartic acid) mutant enhanced transcription of the pro-apoptotic target 
Noxa and restored apoptosis in HSC-3 cells [168]. A study with knock-in mice 
expressing the human TP53 gene with the S46A mutation partially supports the 
idea that S46 has a physiological role in differentially regulating cell cycle arrest 
and apoptosis. The mutant mice, compared to knock-in mice expressing the wild-
type human TP53 gene, displayed modestly reduced p53 transcription of some 
pro-apoptotic targets and compromised apoptosis but not cell cycle arrest, 
although the effects were tissue-specific  [169].  
1.5.4.1c Phosphorylation at Ser392 
Phosphorylation of C-terminal S392 in response to Ultra-Violet (UV) light 
activates specific DNA binding through the stabilization of the p53 tetramer [34]. 
Knock-in mice with a S389A (human S392A) mutation displayed normal p53 
stability but an increased predisposition to UV-induced skin cancer as well as 
altered expression of p53 target genes compared to wild-type mice [170-172], 
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supporting a physiological role for S392 phosphorylation in the tumor suppressive 
responses of p53 to UV. However, some studies report a correlation between 
S392 hyper-phosphorylation and poor prognosis, advanced tumor stage and tumor 
grade in p53-positive cancers [173,174]. How does a tumor-suppressive 
modification acquire tumor-promoting functions? Perhaps S392 phosphorylation 
enhances the tetramer formation of certain gain-of-function p53 mutants, turning 
these mutants into more potent oncoproteins. Further investigation is needed to 
determine whether S392 phosphorylation is common to both wild-type and 
mutant p53, and if so, how it might contribute to tumor progression.  
1.5.4.2 Ubiquitin-like modifications 
p53 is targeted by two ubiquitin-like proteins, Small Ubiquitin-like Modifier 
(SUMO) and Neural precursor cell Expressed Developmentally Down-regulated 
protein 8 (NEDD8), both of which are evolutionarily conserved in eukaryotes and 
resemble ubiquitin in both their three-dimensional structure and their mechanism 
of conjugation through lysines [175-177]. p53 is sumoylated at a single site K386 
by members of the Protein Inhibitor of Activated Stat (PIAS) family and Topors 
[178,179]. Neddylation of p53 is mediated by HDM2 and F-box protein 11 
(FBXO11): HDM2 catalyzes the neddylation of three C-terminal lysines (K370, 
K372 and K373) that are also targeted for ubiquitination [180], FBXO11 
neddylates two lysines (K320 and K321) [181]. Unlike ubiquitination, 
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neddylation and sumoylation have not been demonstrated to affect p53 stability or 
localization. Neddylation inhibits p53 transcriptional activation activity [180,181], 
whereas the functional consequences of K386 sumoylation is interesting, albeit 
not well-defined; some reports have linked it to increased p53 transcriptional 
activity and premature senescence [178,182-184].  
It is noteworthy, that the low abundance of SUMO- or NEDD-8 modified p53 
in vivo, normally less than 5% of total cellular p53, poses a challenge for defining 
the cellular roles of these modifications. Reconstituted systems allow robust 
testing of the roles of these ubiquitin-like modifications in vitro, but are unlikely 
to recapitulate the physiological conditions in which these modifications occur. It 
remains to be determined under what circumstances sumoylation and neddlyation 
might affect p53 function. 
1.5.4.3 Methylation 
The large number of lysine and arginine residues in p53 presents the potential 
for regulation by methylation (Figure 1). Arginine methylation has only been 
shown for one methyltransferase, Protein Arginine N-Methyl Transferase 5 
(PRMT5) [185,186], which targets R333, R335 and R337 in the tetramerization 
domain, and methylation of these residues differentially affect the target gene 
specificity of p53 [186]. p53 lysine methylation is better understood: p53 is 
monomethylated by three different Lysine Methyl Transferases (KMTs) and 
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dimethylated by at least two KMTs [187]. The functional consequences of p53 
lysine methylation can be either activating or repressive, depending on the 
location of the modification and the number of methyl groups attached. 
Monomethylation at K372 is mediated by SET7/9 (also known as KMT7) and 
this modification promotes the transactivation of target genes [188]. SET8 (also 
known as KMT5A)-mediated K382 monomethylation and SMYD2 (also known 
as KMT3C)-mediated K370 monomethylation repress p53 transcriptional activity 
[189,190]. G9A (also known as KMT1C) and G9A-like Protein (GLP, also known 
as KMT1D) dimethylate p53 at K373, thereby negatively regulating p53-mediated 
apoptosis [191]. Interestingly, however, conjugation of a second methyl group to 
K370 (K370me2), by a currently unknown enzyme, leads to a distinct functional 
consequence from monomethylation. K370me2 increases in response to DNA 
damage and promotes p53 function by facilitating the association of p53 with the 
coactivator p53 Binding Protein 1 (53BP1) [192]. Lysine Specific Demethylase 1 
(LSD1, also known as KDM1) preferentially removes this positive-acting second 
methyl group thereby repressing p53 function by inhibiting the association of p53 
with 53BP1 [192]. These findings suggest that p53 methylation and 
demethylation dynamically regulate p53 function, at least in part by allowing or 
disallowing p53 binding to coactivators. 
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Interestingly, there appears to be crosstalk between p53 methylation at 
different sites and between p53 methylation and acetylation. Activating 
methylation of K372 inhibits the repressive methylation of K370 by preventing 
SMYD2 binding to p53 [189]. Moreover, the repressive methylation of K382 
normally prevents acetylation at this same site by CBP/p300 [190]. Upon DNA 
damage, the level of methylation at K382 decreases, reversing its inhibitory effect 
and allowing CBP/p300 acetylation of K382 and thereby promoting p53 activity. 
Together, the interplay between p53 methylation sites as well as between p53 
methylation and acetylation provide mechanisms for triggering a rapid increase in 
p53 transcriptional activity in response to stress. 
The presence of negatively acting lysine methylation sites and KMTs that 
normally maintain p53 in an inactive state suggests the possibility that abnormally 
high levels of KMTs could be oncogenic. Indeed, the SET domain containing 
methyltransferase G9A is upregulated in many cancer cell types and its homolog 
GLP is also overexpressed in brain tumors and multiple myeloma [191]. 
1.5.4.4 Acetylation 
The acetylation of p53 is a powerful mechanism for activating function. The 
significance of p53 acetylation is three-fold: (i) it promotes p53 stabilization by 
excluding ubiquitination on the same site; (ii) it inhibits the formation of 
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HDM2/HDMX repressive complexes on target gene promoters; and (iii) it recruits 
cofactors for the promoter specific activation of p53 transcriptional activity. 
Ten acetylation sites have been identified for p53, and the Histone Acetyl 
Transferases (HATs) responsible for these modifications include the structurally 
related p300 (also known as K(lysine) acetyltransferase 3B (KAT3B)) and CREB-
Binding Protein (CBP, also known as KAT3A), P300/CBP-Associated Factor 
(PCAF, also known as KAT2B) and the MYST (named for members MOZ, 
Ybf2/Sas3, Sas2 and Tip60) family HATs, Tat-Interactive Protein of 60 kDa 
(TIP60, also known as KAT5) and human Males absent On the First (hMOF, also 
known as MYST1/KAT8) [25,193-195] (Fig. 1). 
1.5.4.4a Acetylation at the C-terminus 
Six lysine residues (K370, K372, K373, K381, K382 and K386) in the C-
terminal regulatory domain are acetylated by CBP/p300 and ubiquitinated by 
HDM2 [193] (Fig. 1). Acetylation in tissue culture systems activates sequence-
specific binding of p53 to DNA and its transcriptional activation activity and 
enhances the stability of p53, owing to the mutual exclusion of acetylation and 
ubiquitination. Nevertheless, despite some cell type-specific differences in 





 knock-in mice) generally exhibited no major difference in cell 
cycle control, apoptosis or tumor suppression [196,197], which is in line with the 
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fact that mutation in the p53 C-terminal regulatory domain is rarely found in 
human cancers (UMD_TP53 Mutation database http://p53.free.fr/). 
1.5.4.4b Acetylation at Lys320 
K320 in the tetramerization domain is acetylated by PCAF [198]. It has been 
reported that the competition between the mutually exclusive ubiquitination and 
acetylation of K320 tips the cell fate balance. The atypical E3 ubiquitin ligase 
E4F1 mediates non-degraded K48-linked oligo-ubiquitination of p53 on K320, 
and competes with PCAF mediated acetylation [199]. High levels of K320 
ubiquitination resulting from E4F1 overexpression specifically favors cell 
survival by promoting p53-mediated induction of p21 [199]. This is supported by 
studies using K317R (equivalent to human K320R) knock-in mice, showing 
increased expression of pro-apoptotic target genes and enhanced p53-dependent 
apoptosis upon irradiation [200], suggesting apoptotic repression by K320 
acetylation.  
1.5.4.4c Acetylation in the DNA binding domain 
Two additional acetylation sites, K120 (K117 in mice, acetylation mediated 
by TIP60/hMOF) [194,201] and K164 (K161 and K162 in mice, acetylation by 
CBP/p300) [155] were discovered in the DNA binding domain.  Importantly, both 
K120 and K164 are recurrently mutated in cancer (UMD_TP53 Mutation 
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database http://p53.free.fr/), implying that these two modifications might have 
profound and nonredundant effects on p53 function.  
K120 acetylation is indispensable for the activation of target genes involved in 
apoptosis but not cell cycle arrest [194,201], suggesting a means for controlling 
promoter specificity and hence cell fate. Indeed, in p53
K117R
 knock-in mice p53-
dependent cell cycle arrest and senescence remain intact but apoptotic induction 
following ionizing radiation is completely abrogated [98], confirming the 
indispensability of K120 acetylation to p53-mediated apoptosis.  Additionally, 
K120 acetylation might be required for p53 to effectively displace the 
proapoptotic protein BCL2-Antagonist/Killer 1 (BAK) from the oncoprotein 
Myeloid Cell Leukemia sequence 1 (MCL-1) at the mitochondria [202]. 
Therefore, it is probable that K120 acetylation by TIP60 contributes to both 
transcription-dependent and transcription-independent apoptotic functions of p53.  
In cell culture based assays using human p53, individual K to R mutation can 
be compensated for by acetylation at other sites; however the collective mutation 
of eight acetylation sites (p53
8KR
: mutation at K120, K164, and six CBP/p300-
targeted C-terminal sites) completely abolishes p53-mediated cell cycle arrest and 
apoptosis [155], demonstrating that acetylation is indispensible for the canonical 
p53 functions. Mechanistically, acetylation allows p53 to evade HDM2 and 
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HDMX repression by blocking recruitment of HDM2 and HDMX to target gene 
promoters [155].  
In mice, however, the collective loss of acetylation at K117 (human K120) 
and K161/K162 (human K164) seems sufficient to recapitulate the phenotypes 




 knock-in mice are completely deficient in 
eliciting growth arrest, apoptosis, or senescence in vivo [98], confirming the 
physiological importance of acetylation in the transcription activation of 
canonical p53 targets.  
1.5.4.4d Deacetylation by HDACs and SIRT1 
Equilibrium in the acetylation of p53 is maintained by the Histone 
Deacetylases (HDACs), HDAC1 and Sirtuin 1 (SIRT1) [203,204]. SIRT1 
preferentially deactylates p53 at K382 and has a profound negative impact on the 
capacity of p53 to induce the expression of target genes involved in apoptosis, 
such as PUMA and BAX. Thymocytes of Sirt1-deficient mice exhibit p53 
hyperacetylation and increased radiation-induced apoptosis compared to wild-
type thymocytes [205]. SIRT1 is negatively regulated at the transcriptional level 
by Hypermethylated In Cancer 1 (HIC1) and at the translational level by the 
microRNA (miR)-34a [206,207], both of which are targets of p53 [208-212]. 
SIRT1 expression is elevated in leukemia [213], prostate cancer [214] and skin 
cancer [215], and it is negatively regulated by Deleted in Breast Cancer 1 (DBC1) 
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[216,217], supporting a role for SIRT1 in tumorigenesis. However, the 
suppression of intestinal tumorigenesis and colon cancer growth in a β-catenin-
driven mouse model of colon cancer by ectopic induction of Sirt1 [218] suggests 
that it also has tumor-suppressive properties. 
The evidence that SIRT1 harbors both tumor-promoting and tumor-
suppressing functions generates interest in developing SIRT1-targeted drug 
therapies for cancer treatment [219]. The most promising SIRT1 inhibitors 
discovered to date are tenovin-1 and its more water-soluble derivative, tenovin-6 
[220]. At low micromolar concentrations, tenovins potently inhibit the 
deacetylase activities of SIRT1 and SIRT2, significantly increase the level of p53 
K382 acetylation in tissue culture and decrease tumor growth in xenograft mouse 
tumor models. Studies on activators of SIRT1 focus on resveratrol, which is 
abundant in grapes. Although dietary intake of resveratrol delays aging in mice 
[221], more studies are needed to assure that resveratrol activation of Sirt1 does 
not impose cancer susceptibility. 
1.5.4.5 Concluding remarks 
Although biochemical and cell culture based studies have highlighted the 
crucial role of a number of post-translational modifications in the activation of 
p53 transcription activity, the relatively mild and tissue/cell type-specific 
phenotypes of many knock-in mice with a single point mutation that abolishes a 
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certain modification suggest functional redundancy, perhaps important for the 
“fail-proof” regulation of p53 considering its central role in tumor suppression. 
Although each site/modification might only fine-tune p53 function, the numerous 
possible combinations of different modifications could dictate p53 activity in a 
promoter-specific manner, allowing p53 to exert a spectrum of functions. 
 
The striking phenotype of the p53
3KR
 mice, however, undeniably underscores 
the absolute requirement for p53 acetylation in activating the transcription of 
canonical targets involved in the classic growth arrest, apoptosis and senescence 
response pathways.  
 
1.6 Summary 
Although accumulating evidence supports the indispensability of acetylation 
in the activation of p53 function and indicates cell fate modulation, the underlying 
mechanisms are not completely understood.  The experiments in this study were 
designed to identify novel regulators of p53 acetylation and to study the 
mechanisms modulating p53-mediated cell fate decision.  
In this study we identify p90 and UHRF1 as two novel members of the p53 
regulatory network.  Although both function upstream of the TIP60-p53 interplay, 
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they act through distinct and opposing mechanisms to dynamically modulate 









DIFFERENTIAL EFFECTS ON p53-MEDIATED CELL 




2.1  Introduction 
p53 was the first nonhistone protein known to be regulated by acetylation and 
deacetylation [25,203]. There is accumulating evidence indicating that acetylation 
of p53 plays a major role in activating p53 function during stress responses 
[222,223]. Following early findings of C terminus p53 acetylation [25], the Gu 
team and others recently showed that p53 is also acetylated by TIP60 (also known 
as KAT5)/MOF (human ortholog of males absent on the first) at residue Lys120 
(K120) within the DNA-binding domain [194,201,224]. K120 acetylation is 
crucial for p53-mediated apoptosis but has no obvious effect on p21 expression, 
an essential target of p53-mediated growth arrest [98]. Notably, although TIP60 is 
required for K120 acetylation of p53 in vivo, the levels of K120 acetylation are 
dynamically regulated in vivo and the interaction between p53 and TIP60 is not 
very stable, indicating that additional regulators may play a role in controlling 
K120 acetylation and subsequent p53-mediated apoptotic response [225-227].  
Through biochemical purification, we identified p90 as a unique regulator for 
p53. p90, also called CCDC8 (coiled-coil domain containing 8), which was 
previously found down-regulated in human cancer cells [228,229], interacts with 
p53 both in vitro and in vivo. Knockdown of p90 has no obvious effect on p53-
mediated activation of p21 but specifically abrogates its effect on p53 upregulated 
modulator of apoptosis, also known as Bbc3 (PUMA) activation. Moreover, p90 
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also interacts with TIP60 and promotes TIP60-dependent Lys120 acetylation of 
p53, therefore enhancing the apoptotic response of p53. These data reveal p90 as 
an upstream regulator of the TIP60-p53 interaction and demonstrate that p90 is 




2.2  Results 
2.2.1 Identification of p90 as a unique component of p53-associated 
complexes 
To further elucidate the mechanisms of p53-mediated promoter-specific 
activation in vivo, p53-associated protein complexes were isolated from human 
cells. Attempts to purify p53-containing protein complexes were hindered in the 
past because cells cannot tolerate expressing even low levels of wild-type p53. 
Interestingly, recent studies by the Gu team indicate that p53
8KR
, in which all 
eight p53 acetylation sites are mutated to arginine, is inactive in inducing cell 
cycle arrest or apoptosis [155]. Moreover, p53
8KR
 retains the capacity to bind 
target gene promoters as well as to activate the p53-HDM2 feedback loop, 
suggesting that p53
8KR
, unlike the hot spot tumor mutant p53
H175R
, may retain a 
similar conformation as wild-type p53 in human cells. Therefore we have utilized 
an H1299 p53-null lung carcinoma cell line that stably expresses a double tagged 
human p53
8KR
 mutant protein with N-terminal FLAG and C-terminal HA epitopes 
(FLAG-p53
8KR
-HA) (Fig. 3A). 
To ensure physiological interactions, H1299 derivatives were selected such 
that the expression level of the ectopic p53
8KR
 protein is not much higher than 
endogenous p53 in HCT116 colon cancer cells upon DNA damage treatment. As 
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expected, HDM2 is activated in the p53
8KR 
stable line to a similar level compared 
to that induced by DNA damage in HCT116 cells. Consistent with previous 
findings, pro-apoptotic and growth arrest targets such as PUMA and p21 are not 
activated in the p53
8KR




Figure 3. Construction of p53
8KR
 stable line in H1299 
(A) Schematic representation of the p538KR protein used for protein complex 
purification. Mutations of acetylation sites are indicated. TAD, 
transcription activation domain; PRD, proline rich domain; DBD, DNA-
binding domain; TD, tetramerization domain; CTD, C-terminal regulatory 
domain.  
(B) Characterization of H1299 cells stably expressing p538KR. Total cell 
extracts from FLAG-p53
8KR
HA/H1299 stable cell line and HCT116 cells 
with or without 8hr treatment with 20 μM etoposide were assayed by 
Western blot analysis using antibodies against p53, β-actin, Mdm2, 










-containing complexes, cell extracts from the stable line 
were subjected to a two-step affinity chromatography previously described [126]. 
The tandem affinity-purified p53-associated proteins were analyzed by liquid 
chromatography (LC) MS/MS. As expected, known p53 binding proteins such as 
HDM2, tumor protein 53 binding protein 1 (p53BP1), USP7, and the CREB 
binding protein (CBP) were identified as specific components of the p53 complex 
(Fig. 4A). In addition, MS analysis of a protein band p90 (with the apparent size 
at approximately 90 kDa molecular mass) revealed six peptide sequences matched 
with a signal cDNA sequence in the database, which is also named CCDC8 (Fig. 
4B). Because none of the peptide sequences of p90 were identified from the 
control complexes purified in parental H1299 cells, p90 is likely a unique binding 
partner of p53.  
The cDNA of p90/CCDC8 encodes a 538 amino acid protein possessing no 
known functional domains other than two small coiled-coil regions that are likely 
to mediate protein–protein interactions (Fig. 4B). Although p90/CCDC8 has been 
reported as a candidate tumor suppressor gene in renal cell carcinoma (RCC), the 




Figure 4. Identification of p90 as a component of a p53-containing protein 
complex 
(A) Silver staining of purified p538KR containing protein complex. Peptide 
sequences identified from the mass spectrometric analysis are presented. 
(B) Schematic representation of the p90 protein. p90 contains two coiled-coil 













2.2.2  p90 is a bona fide p53 interacting protein 
To investigate a role for p90 in regulating p53 function in vivo, the interaction 
between p90 and p53 was first tested. Thus, H1299 cells were transfected with 
expression vectors for FLAG-tagged p53 and HA-tagged p90, and Western blot 
analysis revealed that p90 is readily detected in p53-associated 
immunoprecipitates (Fig. 5A).  
To further elucidate this interaction under physiological settings, a polyclonal 
antiserum was then raised against the full-length p90 protein. Upon Western blot 
analysis, the affinity-purified antibody specifically detected in human cells an 
approximately 90 kDa polypeptide, the level of which decreases significantly 
after treatment with p90-specific siRNA oligos (Fig. 5B). To investigate the 
interaction between endogenous p90 and p53 proteins, extracts from U2OS 
osteosarcoma cells were immunoprecipitated with α-p53 antibody or with the 
control IgG. As expected, the α-p53 antibody immunoprecipitated endogenous 
p53; more importantly, p90 is easily detected in the immunoprecipitates obtained 
with the α-p53 antibody but not the control IgG (Fig. 5C, lanes 2 and 3), 




Figure 5. p90 interacts with p53 in vivo 
(A) p90 coimmunoprecipitates with p53 in an overexpression system. H1299 
cells were transiently transfected with plasmid DNA expressing HA-p90 
or/and FLAG-p53. The cell extracts and the M2 immunoprecipitates (IP) 
were analyzed by Western blot analysis using α-HA and α-p53 antibodies. 
(B) Purified p90 antisera specifically recognizes p90 protein. U2OS cells 
were transiently transfected with either control siRNA or p90-specific 
siRNA. Whole cell lysates were analyzed with α-90 antisera. 
(C) p90 interacts with p53 endogenously. Total cells extracts from U2OS cells 
were immunoprecipitated with α-p53 (DO-1) antibody or a control mouse 
IgG . Extracts and immunoprecipitates were assayed by Western blot 
analysis using α-p90 and α-p53 antibodies. 















An in vitro GST-pulldown assay was performed to further assess direct 
interaction. p53 can be divided into an N-terminal (NT) fragment containing the 
transactivation domain, a middle fragment (M) containing the DNA-binding 
domain, and a C-terminal (CT) fragment containing the tetramerization domain as 
well as the regulatory domain. Purified recombinant GST-tagged p53 full-length 
and fragment proteins were incubated with in vitro translated 
35
S-methione-
labeled HA-p90. Following immobilization with GST resins and recovery of 
captured complexes using reduced glutathione, the eluted complexes were 
resolved by SDS-PAGE and analyzed by autoradiography. 
35
S- methionine-
labeled HA-p90 strongly bound immobilized GST-tagged full length and CT 
fragment of p53 (Fig. 6, lanes 2 and 5), but not the NT and middle fragments of 
p53 or GST alone (Fig. 6, lanes 3, 4, and 6). These data demonstrate that p90 





Figure 6. p90 interacts with the C-terminal domain of p53 in vitro 
The bacteria purified full-length and fragmented GST-p53 fusion proteins or GST 
were used in the GST-pulldown assay with in vitro translated 
35
S-methionine 
labeled HA-p90 protein. The complexes were captured with GST sepharose beads 
and eluted with reduced glutathione. The eluted complexes were resolved by 
SDS-PAGE and analyzed by autoradiography. The levels of the GST fusion 







We further mapped the binding fragment on p90. The N-terminal and C-
terminal fragments of p90 were subcloned into HA expression vector, and in vitro 
translated 35S-methionine labeled HA-p90 fragments were incubated with GST-
p53 or GST. Following capture and elution, the complexes were resolved by SDS-
PAGE and analyzed by autoradiography. The full length p90 protein and the N-
terminal fragment, but not the C-terminal fragment of p90 bound GST-p53 (Fig. 
7). These data demonstrate that the N-terminal fragment of p90 protein and the C-




Figure 7. p90 interacts with p53 through its N-terminal fragment 
The N-terminal and the C-terminal fragments of p90 are subcloned into HA-
tagged expression vector. The bacteria purified GST-p53 or GST were used in the 
GST-pulldown assay with in vitro translated 
35
S-methionine labeled HA-p90 
fragments, essentially as in Fig. 7. The eluted complexes were resolved by SDS-







Because p90 was identified in the p53 complex purified from whole cell 
extracts, we assessed the cellular localization of the p90–p53 interaction. To this 
end, U2OS cell line stably expressing FLAG and HA double tagged p90 was 
established. Using parental U2OS cells as control, cell extracts from the p90 
stable line were fractionated, and both nuclear and cytoplasmic fractions were 
immunoprecipitated with M2/FLAG agarose beads. Western blot analysis showed 
that p53, as expected, localizes mainly in the nuclear fraction, whereas p90 is 
present in both fractions but more so in the cytoplasmic fraction (Fig. 8A). 
Furthermore, in the M2 immunoprecipitate, p53 is primarily found in the nuclear 
fraction (Fig. 8A). The difference in p90/p53 ratio in the cytoplasmic and nuclear 
fractions as well as the p53 abundance in the nuclear M2 immunoprecipitate 
indicate that, although p90 is present in both the cytoplasm and the nucleus, it 
interacts with p53 predominantly in the nucleus. In agreement with the 
fractionation experiment, immunostaining of HA-p90 transfected U2OS cells 
revealed that p90 is localized to both the nucleus and the cytoplasm, regardless of 
etoposide challenge. p53 was stabilized following etoposide treatment and co-
localized with p90 in the nucleus. (Fig. 8B). These data demonstrate that p90 





Figure 8. p90 interacts with p53 in the nucleus 
(A)  p90 localizes in both the cytoplasm and nucleus but interacts with p53 
predominantly in the nucleus. Parental U2OS or FLAG-HA-p90/U2OS 
stable cell line were fractionated. Extracts and M2 immunoprecipitates 
from the cytoplasmic and nuclear fractions were assayed by Western blot 
analysis using α-HA and α-p53 antibodies. β-tubulin and proliferating cell 
nuclear antigen (PCNA) were used as cytoplasmic and nuclear protein 
markers, respectively. 
(B) p90 localization remains unchanged regardless of DNA damage and p90 
colocalizes with activated p53. U2OS transiently transfected with 
expression plasmid for HA-p90 was subjected to 8hr of etoposide 













2.2.3 Inactivation of p90 attenuates p53-mediated activation of PUMA but 
not p21 
To understand the physiological role of p90, we examined whether 
inactivation of endogenous p90 has any effect on the stability and functions of 
p53. To this end, U2OS cells were transfected with a p90-specific (p90-RNAi#1) 
siRNA oligo or a control (control-RNAi) siRNA oligo. As shown in Fig. 9A, 
lanes 1 and 2, the level of endogenous p90 polypeptides was severely re- duced 
after transfection with p90-RNAi. p53 protein level was unaffected by p90 
ablation, suggesting that p90 does not regulate p53 stability. We then assessed the 
effect of p90 inactivation on the level of two important p53 downstream targets: 
the growth arrest target p21 and the apoptotic target PUMA. Surprisingly, p90 
ablation displayed differential effects on the two different endogenous targets: the 
level of PUMA was significantly reduced, whereas p21 expression remained 
unchanged. To exclude off-target effects, cells were treated with three additional 
p90 siRNAs (p90-RNAi#2, p90-RNAi#3; p90-RNAi#4) that target different 
regions of the p90 mRNA. Again, the levels of PUMA were decreased by p90 
knockdown, although there was no significant change for the levels of p53 and 
p21 (Fig. 9A, lanes 3–5).  
Because p53 is strongly activated upon DNA damage and regulates 
downstream targets, we wanted to assess whether p90 affects p53 and 
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downstream target activation upon DNA damage. U2OS cells were transfected 
with p90-specific siRNA oligos followed by treatment with the DNA damage 
reagent etoposide. As expected, p53 levels increased drastically upon DNA 
damage (Fig. 9B, lane 2 vs. lane 1), and notably, RNAi-mediated ablation of p90 
displays no effect on p53 accumulation following etoposide treatment (Fig. 9B, 
lane 4, 6, 8, and 10 vs. lane 2). p21 was strongly induced upon treatment, however, 
damage-induced PUMA expression was severely attenuated in the cells treated 




Figure 9. p90 inactivation reduces basal PUMA level and differentially 
affects PUMA and p21 induction upon DNA damage 
(A) p90 RNAi does not affect p53 stability or p21 basal level but reduces basal 
PUMA expression. U2OS cells were transiently transfected with either 
control siRNA or four different p90-specific siRNA oligos. Cell extracts 
were assayed by Western blot analysis using the indicated antibodies.   
(B) p90 RNAi attenuates PUMA but not p21 activation upon DNA damage. 
U2OS cells transfected with the indicated siRNAs were treated with or 
without 20 μM etoposide for 8hr. Total cell extracts were assayed by 





















To validate that the differential effect of p90 on PUMA and p21 is p53 
dependent, we inactivated both p53 and p90 in U2OS using RNAi prior to 
etoposide treatment. In cells transfected with the control siRNA, p53 accumulates 
and both PUMA and p21 are activated significantly upon treatment (Fig. 10, lanes 
1 and 2). In a p53-deficient background, DNA damage fails to activate PUMA 
and p21 (lanes 3 and 4), and more importantly p90 ablation displayed no effect on 
PUMA and p21 in the absence of p53 (lanes 5 and 6). Taken together, these data 
demonstrate that p90 inactivation differentially affects PUMA and p21 induction 





Figure 10. Differential regulation of PUMA and p21 activation by p90 is 
dependent on p53 
p53 alone, or both p53 and p90 were inactivated in U2OS cells using RNAi. 
Subsequently, cells were treated with or without 20 μM etoposide for 8 hr before 






2.2.4 p90 is required for p53-mediated apoptosis upon DNA damage 
To further confirm the differential effects on p53-mediated activation of p21 
versus PUMA, we collected the cells at different time points following treatment 
with etoposide. At all time points, p53 accumulation and p21 activation were 
unaffected by p90 ablation but PUMA induction was severely attenuated (Fig. 
11A, lanes 5 and 6 vs. lanes 2 and 3).We further confirmed that p90 ablation 
affected p53-dependent activation of p21 and PUMA at the transcription level by 
examining the mRNA levels of these targets. Indeed, basal PUMA mRNA was 
reduced in samples treated with p90-RNAi, consistent with our finding that p90 
ablation reduces basal PUMA protein level (Fig. 11A). PUMA activation was 
attenuated at the mRNA level following p90 ablation, whereas p21 mRNA level 
increased upon etoposide treatment at all time points and remained unaffected in 
samples treated with p90-RNAi. 
To further confirm these differential effects of p90 in p53 responses, we 
repeated these experiments in the cells treated with another DNA damage reagent 
doxirubicin. Again, we observed the differential effects of p90 on p53-dependent 
p21 and PUMA activation upon doxirubicin treatment (Fig. 11B, lanes 6–8 vs. 
lanes 2–4). These results suggest that p90 is crucial for p53-dependent activation 




Figure 11. Inactivation of p90 attenuates p53-dependent PUMA activation in 
time point experiments 
(A and B) p90 RNAi reduces PUMA but not p21 activation upon DNA damage. 
U2OS cells transiently transfected with either control siRNA or p90-specific 
siRNA were treated with 20 μM etoposide or 0.34 μM doxirubicin for the 
indicated time. Cell extracts were analyzed by Western blot analysis using the 
indicated antibodies. Total RNA were isolated from the same experiment. 
















We therefore speculated whether the attenuation of PUMA activation by loss 
of p90 can be translated into a phenotypic effect on apoptosis. To this end, we 
transfected U2OS cells with either control siRNA or p90 siRNA prior to 
etoposide treatment. Cells were collected at different timepoints, stained with 
propidium iodide (PI), and analyzed by flow cytometry for apoptotic cells 
according to DNA content. As shown in Fig. 12A, basal level sub-G1 content is 
minimally affected by inactivation of p90. However, following 18hr or 24hr of 
etoposide treatment, an average of 18.67% or 26.84% of cells transfected with 
control siRNA were apoptotic, whereas only 8.04% or 11.49% of cells transfected 
with p90 siRNA were apoptotic (Fig. 12B). These data demonstrate that p90 is 




Figure 12. Inactivation of p90 impairs p53-mediated apoptosis upon damage 
(A) FACS analysis of p90-inactivated U2OS cells treated with etoposide. 
U2OS cellstransiently transfected with either control siRNA or p90 siRNA 
were treated with 20 μM etoposide for the indicated time. Cells were fixed 
in cold methanol, stained with propidium iodide and subjected to DNA 
content analysis by flow cytometry.  
(B)  p90 RNAi attenuates apoptosis. Percentages of apoptotic cells from (A) 
are presented. Values are an average of three independent experiments. 















2.2.5 Mechanistic insights into p90-mediated effect on p53-dependent 
apoptotic responses 
Previous studies demonstrated that p53 acetylation at Lys120 (p53 AcK120) 
by TIP60 is indispensable for apoptosis but not required for growth arrest 
[194,201], leading to our speculation that p90 may regulate p53-mediated PUMA 
activation through promoting TIP60-dependent acetylation of p53 at K120. To 
investigate the mechanism underlying the effect of p90 on the apoptotic target 
PUMA, we first assessed the interaction between p90 and TIP60. To this end, 
H1299 cells were transfected with expression vectors for TIP60 and FLAG/HA 
double-tagged p90. Western blot analysis revealed that TIP60 is readily detected 
in p90 associated immunoprecipitates (Fig. 13A). Using a GST-pulldown assay, 
we further tested the in vitro interaction of TIP60 and p90. As shown in Fig. 13B, 
TIP60 bound to immobilized GST-tagged p90 but not GST alone, demonstrating 
that p90 and TIP60 interacts directly. Further, p90, TIP60 and p53 form a ternary 




Figure 13. p90 interacts with TIP60 and forms a ternery complex with TIP60 
and p53 
(A) TIP60 coimmunoprecipitates with p90 in an overexpression system. 
H1299 cells were transiently transfected with the plasmid DNA expressing 
TIP60 or/and FLAG-HA-p90. Cell extracts and M2 immunoprecipitates 
were assayed by Western blot analysis using α-TIP60 and α-HA 
antibodies. 
(B) p90 interacts with TIP60 in vitro. The GST-p90 fusion protein or GST 
alone was used in the GST-pulldown assay with in vitro translated 
35
S-
methione labeled FLAG-HA-TIP60 protein. The immobilized complexes 
were resolved by SDS-PAGE and analyzed by autoradiography. 
(C) Total cell extracts from H1299 cells transfected with HA-p0, F-p53 and 
Tip60 are subjected to a 2-step immunoprecipitation using M2/Flag and 
HA agarose beads. Extracts and eluates are assayed by Western Blot using 
antibodies against HA, p53, and TIP60. 










To investigate the role of p90 in p53 K120 acetylation by Tip60, we examined 
whether TIP60-mediated p53 acetylation is modulated by p90 status. As expected, 
in a cotransfection system, p53 was readily acetylated by TIP60. Notably, 
although p90 itself does not acetylate p53, p53 acetylation by TIP60 was 
significantly enhanced upon p90 expression (Fig 14A). These data demonstrate 
that p90 promotes the aceylation of p53.  
In order to confirm the effect of p90 on Tip60-mediated p53 K120 acetylation 
under physiological settings, we inactivated p90 in U2OS cells via RNAi and 
assessed endogenous acetylation of p53 at K120. Because the steady-state levels 
of K120 acetylation are dynamically regulated by both acetylases and 
deacetylases, in order to exclude the potential effect on p53 acetylation levels by 
deacetylases, cells were treated with deacetylase inhibitors trichostatin A (for 
inhibiting histone deacetylase 1/histone deacetylase 2-mediated deacetylation of 
p53) and nicotinamide (for inhibiting Sirt1-mediated deacetylation of p53) prior 
to harvesting [201,225,227]. Cell extracts were immunoprecipitated with α-Ac-
p53K120 or control IgG. As shown in Fig. 14B, p53 acetylation at K120 was 
easily detected in the cells with the deacetylase inhibitor treatment; however, the 
levels of p53 acetylation at K120 were significantly reduced upon p90 
knockdown (Fig. 14B, lane 4 vs. lane 2). Taken together, these data indicate that 
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p90 is a critical cofactor for p53-mediated apoptosis through promoting K120 




Figure 14. p90 promotes TIP60-mediated p53 acetylaiton at K120 
(A) p90 promotes p53 acetylation by TIP60 at K120. H1299 cells were 
transiently transfected with plasmid DNA expressing FLAG-p53, Tip60, 
and/or HA-p90. Cell extracts and M2 immunoprecipitates were assayed by 
Western blot analysis using antibodies against HA, p53, TIP60, and p53-
AcK120.   
(B) Inactivation of p90 significantly reduces p53 acetylation at K120. U2OS 
cells were transiently transfected with either control siRNA or p90 siRNA, 
and treated with 1 μM trichostatin A (TSA) and 5 mM nicotinamide (NTA) 
6 h prior to harvesting. Cell extracts and immunoprecipitates obtained 
with α-Acp53K120 or control IgG were analyzed by Western blot analysis 













Our findings reveal that p90 is a p53 interacting protein with differential 
effects on p53-mediated activation of target genes. Here, we have demonstrated 
that p90 is a bona fide p53 interacting protein and that this interaction primarily 
occurs in the nucleus. Inactivation of p90 attenuates apoptosis due to 
downregulation of p53-mediated PUMA activation upon DNA damage. However, 
p90 does not appear to affect growth-arrest targets such as p21. To dissect the 
molecular mechanism underlying this differential regulation, we found that p90 
interacts with the TIP60 acetyltransferase and promotes TIP60-mediated 
acetylation of p53 at K120, a posttranslational modification that has previously 
been reported to modulate the decision between cell cycle arrest and apoptosis 
[194,201,224]. Thus, p90 likely serves as an upstream regulator of the p53-TIP60 
interplay that is required for apoptotic signaling and allows for transcription 
induction of PUMA in cells at risk of DNA damage. 
K120 is located within the p53 DNA-binding domain and is recurrently 
mutated in cancer (UMD_TP53 mutation database http://p53.free.fr/). Acetylation 
at K120 is indispensable for activation of pro-apoptotic targets but is not required 
for activation of growth-arrest targets [194,201].  Although the mechanism 
underlying this target specificity remains to be elucidated, it is possible that 
acetylation at K120 may impose specificity through altering the p53 quaternary 
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structure and thus endowing p53 binding to low-affinity response elements that 
are found on pro-apoptotic promoters [232,233].  
We also noticed a small amount of cytoplasmic p53–p90 interaction. 
Cytoplasmic localization of p53 was originally thought to passively block 
transactivation in the nucleus. However increasing evidence suggests cytoplasmic 
p53 has important roles in regulating apoptosis and autophagy. Cytoplasmic p53 
promotes apoptosis through increasing mitochondrial outer-membrane 
permeabilization and release of cytochrome c [66,69,70]. Basal levels of wild-
type p53 in the cytoplasm also inhibits autophagy, although the exact mechanism 
remains to be understood [138]. It will be interesting to explore the possibilities of 
p90 regulating transcription-independent functions of p53 in the cytoplasm. 
It is noteworthy that p90 itself is underexpressed in human tumors, including 
kidney cancer and myeloma, based on the cancer gene expression profile database 
from Oncomine Research [228,229]. In this regard, p90 has also been identified 
as a candidate tumor suppressor gene as hypermethylation and transcriptional 
silencing of the p90 promoter was found in 35% of primary RCC tumor samples 
[230]. It will be interesting to test whether p53-mediated apoptosis is abrogated in 
the human tumors lacking p90 expression and whether reactivation of silenced 
p90 promotes apoptosis thereby contributing to tumor suppression. 
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Finally, protein modifications of the components in the p53 pathway are well 
accepted as the key mechanisms for controlling p53 function during stress 
responses [146,177](2, 35). Interestingly, p90 contains two potential ataxia 
telangiectasia mutated/ataxia telangiectasia and Rad3 related (ATM/ATR) 
phosphorylation sites at Ser-199 and Ser-302 (Fig. 4B). Indeed, in a screen assay 
performed by the Elledge Group [234], a phosphorylated peptide derived from 
p90 was identified as an ATM/ATR substrate. Future investigations are required 
to validate if p90 undergoes damage-induced phosphorylation by ATM/ATR and 
dissect whether p90 phosphorylation modulates its interaction with p53 and Tip60 
as well as p53-mediated apoptotic responses. It is possible that p90 is functionally 
regulated by ATM/ATR mediated phosphorylation during the DNA damage 





2.4 Materials and methods 
Plasmids  
The full-length p90 cDNA was PCR-amplified from Human MGC Verified 
FL cDNA (Open Biosystems) and subcloned into pcDNA3.1/V5-His-Topo vector 
(Invitrogen), pCIN4-FLAG-HA, or pCIN4-HA expression vector [235]. To 
construct the GST-p90 plasmid, cDNA sequences corresponding to the full-length 
p90 were amplified by PCR from other expression vectors and subcloned into 
pGEX-2T (GE Healthcare) vector for expression in bacteria.  
Cell culture 
H1299 and U2OS cells were maintained in DMEM (Cellgro) and HCT116 
cells in McCoy’s 5A medium (Cellgro). All media were supplemented with 10% 
fetal bovine serum (Gibco), 100 I.U./mL penicillin and  100 ug/mL streptomycin 
(Cellgro). The stable cell lines were established by transfecting H1299 or U2OS 
cells with the plasmids pCIN4-FLAG-p538KR-HA and pCIN4-FLAG-HA-p90, 
respectively, followed by selection with 1 mg/mL or 0.5 mg/mL G418 (EMD 
Biosciences). Independent clones were selected and evaluated for expression by 
immunoblot. Transfections with plasmid DNA were performed using the calcium 
phosphate method and siRNA transfections by Lipofectamine2000 (Invitrogen) 




The rabbit polyclonal antibody specific for p90 was generated by Covance. 
Rabbits were immunized with purified full-length GST-p90 protein. Antisera 
from the immunized rabbits were first depleted with a GST-affinity column, then 
affinity purified by use of a GST-p90 affinity column using the Aminolink Plus 
Immobilization kit (Thermo Scientific). Antibodies used for immunoprecipitation 
are p53 (DO-1) from Santa Cruz, α-FLAG M2 affinity gel from Sigma, and α-HA 
affinity gel from Roche. Antibodies used for Western blot analysis are p53 (DO-
1), p53 (FL-393), β-tubulin (D-10), p21 (C-19 and SX118), and PCNA (PC10) 
from Santa Cruz, β-actin (AC-15), PUMA (NT), and FLAG M2 from Sigma, 
Mdm2 (Ab-5) from EMD Biosciences, HA (3F10) from Roche Applied Science.  
α-Acp53K120 antibody has been described [201]. α-TIP60 (CLHF) was a gift 
from Chiara Gorrini and Bruno Amati (European Institute of Oncology, Milan, 
Italy). 
Protein complex purification from H1299/FLAG-p538KR-HA stable cell line 
To purify p53 containing protein complexes, a large scale two-step affinity 
purification was performed using H1299/FLAG-p53
8KR
-HA stable cell line. Cells 
were lysed for 2 hr in cold BC300 buffer [20 mM Tris, (pH 7.9),  300mM NaCl, 
10% glycerol, 0.2 mM EDTA, 0.4% Triton X-100, and freshly supplemented 
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protease inhibitor], then for another 2 hr following addition of equal volume of 
BC0 buffer [20 mM Tris, (pH 7.9),  10% glycerol, 0.2 mM EDTA, and freshly 
supplemented protease inhibitor]. Following high-speed centrifugation (21,885 xg 
for 15 min), the cleared extract was then subjected to overnight 
immunoprecipitation with α-FLAG M2 affinity gel at 4 °C. After five washes 
with BC150 buffer [20 mM Tris, (pH 7.9), 150mM NaCl, 10% glycerol, 0.2 mM 
EDTA, and freshly supplemented protease inhibitor], the bound proteins were 
eluted twice using FLAG-peptide (Sigma) in BC150 buffer for 2 hr each at 4 °C. 
The eluted material was subjected to a second round of immunoprecipitation with 
α-HA affinity gel (Roche). After five washes with BC150 buffer, the bound 
proteins were eluted with 0.1% trifluoroacetic acid in 50% acetonitrile. The eluted 
complexes were then lyophilized using a freeze dryer (FreeZone 2.5Plus, 
Labconco), resuspended in SDS sample loading buffer and assayed by SDS-
PAGE.    
Western blot analysis and immunoprecipitation 
 For Western blot analysis, immunoprecipitation of ectopically expressed 
FLAG-tagged proteins, or from the U2OS FH-p90 stable line, cells were lysed in 
cold FLAG lysis buffer [50 mM Tris-HCl (pH 7.9), 137 mM NaCl, 10 mM NaF, 
1 mM EDTA, 1% Triton X-100, 0.2% Sarkosyl, 10% glycerol, and freshly 
supplemented protease inhibitor cocktail]. For immunoprecipitation, extracts were 
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incubated with the α-FLAG M2 affinity gel (Sigma) at 4 °C overnight. After five 
washes with the lysis buffer, the bound proteins were eluted using FLAG-peptide 
(Sigma) in BC100 for 2 h at 4 °C. The eluted material was resolved by SDS-
PAGE and immunoblotted with antibodies as indicated. To immunoprecipitate 
endogenous p53, cells were lysed in BC100 buffer and cell lysates were pre-
cleared by incubating with 20 uL protein A/G agarose beads (Santa Cruz) for 2 
hours with gentle rotation. The cleared supernatants were incubated with α-p53 
(DO-1) antibody at 4 °C overnight before addition of 20ul of protein A/G agarose 
beads for 4 hours. After five washes with the lysis buffer, the immunoprecipitated 
materials were eluted with the SDS sample buffer with boiling, resolved by SDS-
PAGE and detected with antibodies as indicated. 
Preparation of cytoplasmic and nuclear fractions 
Cytoplasmic extracts were prepared by resuspension of pelleted cells in 
hypotonic buffer [10 mM Tris-HCl (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 
supplemented with fresh protease inhibitor] followed by Dounce homogenization 
(six strokes with Type A pestle) and subsequent low-speed pelleting of nuclei 
(600 xg for 10 min). The supernatant was removed for use as cytoplasmic extract. 
The pellet from the low-speed spin was washed once with hypotonic buffer 
containing 0.1% Nonidet P-40, and further extracted with BC200 [20 mM Tris 
(pH 7.9), 200 mM NaCl, 10% glycerol, 0.2 mM EDTA, 0.4% Triton X-100, 
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supplemented with fresh protease inhibitor]. The nuclear extract was then 
clarified by high-speed centrifugation (21,885 xg for 15 min). For subsequent 
immunoprecipitation, both fractions were adjusted to a final concentration of 150 
mM NaCl and 0.2% Triton X-100. 
GST-pulldown assay 
 GST and GST-tagged protein fragments were purified as described 
previously [236]. 
35
S-methione labeled proteins were prepared by in vitro 
translation using the TNT Coupled Reticulocyte Lysate System (Promega). GST 
or GST-tagged fusion proteins were incubated with in vitro translated 
35
S-
methione-labeled proteins overnight at 4 °C in BC100 buffer containing 0.2% 
Triton X-100 and 0.2% BSA. GST resins (Novagen) were then added, and the 
solution was incubated at 4 °C for 3 h. After five washes, the bound proteins were 
eluted for 1.5 h at 4 °C in BC100 buffer containing 0.2% Triton X-100 and 20mM 
reduced glutathione (Sigma), and resolved by SDS-PAGE. The presence of 
35
S-
labeled protein was detected by autoradiography. 
siRNA-mediated ablation of p90 and p53 
 Ablation of p90 was performed by transfection of U2OS cells with siRNA 







Ablation of p53 was performed by transfection of U2OS cells with siRNA 
duplex oligoset (On-Target-Plus Smartpool L00332900, Dharmacon). Control 
RNAi (On-Target-Plus siControl nontargeting pool D00181010, Dharmacon) was 
also used for transfection. RNAi transfections were performed two times with 
Lipofectamine 2000 at a final concentration of 100 pM according to the 
manufacturer’s protocol (Invitrogen). 72hr after the first transfection, cells were 
either harvested for Western blotting or subjected to drug treatment.  
Immunofluorescent staining 
Cells were washed with lukewarm phosphate buffered saline solution (PBS), 
and fixed with 4% paraformaldehyde in PBS at 37 °C for 30 min, rehydrated for 5 
min in serum-free DMEM, and permeabilized with 0.1% Triton X-100 in PBS for 
10 min at room temperature. Cells were incubated in blocking buffer (1% bovine 
serum albumin (BSA), 5% goat serum in PBS) for 45 min. Primary antibodies (as 
indicated) were added in blocking buffer for 1 hr at room temperature. After three 
washes with 1% BSA/PBS, Alexa Fluor conjugated secondary antibodies were 
added and incubated for 30 min at room temperature. Finally, cells were 


















TIP60 is a ubiquitously expressed and evolutionarily conserved founding 
member of the MYST family of lysine acetyltranferases. It was originally isolated 
in a yeast-2-hybrid screen as a protein interacting with and augmenting the 
function of the potent HIV gene transactivator HIV-1-Tat [237]. Tip60 possesses 
acetyltranferase activity, through acting in multiprotein complexes that are 
structurally and functionally conserved from yeast to human, with specificity for 
histones (core histones H2A, H3 and H4) [238-241] and non histone proteins 
[241-244].   
Histone acetylation occurs at the N-terminal tail and on the surface of the 
nucleosome core. Acetylation removes the positive charge on histones, thereby 
decreasing the affinity of histones to the negatively charged phosphate groups of 
DNA. As a consequence, the local chromatin structure becomes more relaxed, 
often leading to greater levels of gene transcription. Apart from acetylating 
histones, TIP60 can also acetylate transcription factors and directly affect DNA 
binding, or recruit other coactivators/corepressors. TIP60 can positively or 
negatively regulate transcription activation depending on the specific transcription 
factor with which it is complexed. For example, TIP60 promotes the transcription 
activity of HIV-1-Tat [237] and nuclear hormone receptors such as the androgen 
receptor, the estrogen receptor and progesterone receptor [245,246], but  promotes 
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transcription repression when complexed with Signal transducer and activator of 
transcription 3 (STAT3) [247] or TEL [248], which frequently translocates and 
fuses to Acute Myeloid Leukemia protein (AML) in pediatric leukemia.  
In addition to its function in transcriptional regulation, TIP60 plays important 
roles in the DNA damage response pathway: activation of the ataxia telangiectasia 
mutated (ATM) DNA damage sensor is dependent on the acetyltransferase 
activity of TIP60, and TIP60 is recruited to sites of DNA lesions in Drosophila to 
facilitate DNA repair [249,250]. A key study of large-scale inhibitory RNA 
(RNAi) screening identified TIP60 to be essential for p53-dependent cell growth 
arrest, thereby suggesting TIP60 as a component of the p53 pathway [251]. This 
was soon confirmed by studies demonstrating TIP60 interaction with p53 and 
TIP60-mediated p53 acetylation at K120, which specifically favors expression of 
p53-dependent apoptotic targets [194,201]. Although TIP60 is a potent positive 
regulator of p53 activation, the dynamically regulated levels of TIP60-mediated 
K120 acetylation and the unstable interaction between TIP60 and p53 suggests 
additional players in regulating the TIP60-p53 interplay. 
Recent studies have identified Tip60 to be a new member in the 
macromolecular epigenetic regulating protein complex that contains UHRF1 
(Ubituitin-like containing PHD Ring Finger 1, also known as ICBP90 in humans 
and Np95 in mice), the maintenance DNA methyltransferase DNMT1, the de 
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novo DNMT3a/3b, the histone deacetylase 1 (HDAC1), ubiquitin specific 
protease 7 (USP7, also known as HAUSP), proliferating cell nuclear antigen 
(PCNA), and the euchromatic histone lysine N methyltransferase 2 (EHMT2, also 
called G9a) [252-255].  
UHRF1 was originally isolated in a yeast-1-hybrid screen to enhance 
expression of topoisomerase IIα by binding to the CCAAT box of its promoter 
region [256,257]. UHRF1 is a key component and critical coordinator of the 
epigenetic regulating complex. This is made possible by the multiple protein 
modalities of UHRF1 (Fig. 15) that facilitate the coordination of other epigenetic 
regulators through linking DNA methylation and histone modifications. UHRF1 
interacts with PCNA at the replication fork and, through its Set and Ring 
associated (SRA) domain that is distinctive to the UHRF family, recognizes 
hemimethylated DNA [258-260] and tethers DNMT1 to methylate the newly-
synthesized DNA strand [261], thereby maintaining genomic DNA methylation 
patterns. In addition, UHRF1 also recruits G9a to methylate Histone H3K9. 
Trimethylated histone H3K9 is then read by UHRF1 through its tudor domain 
[262], and HDAC1 is recruited through the SRA domain [263]. HDAC1 in turn 
deacetylates histones, causing them to become positively charged and tightly 
bound to the negatively charged DNA, causing heterochromatin formation to 
perpetuate transcription repression of certain tumor suppressor genes.  
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The implication of UHRF1 involvement in tumorigenesis stems from studies 
reporting high UHRF1 expression level in actively proliferating tissues and low 
expression level in quiescent cells and highly-differentiated tissues [256,264]. 
Indeed, UHRF1 was found upregulated in numerous cancers,  including breast 
cancer [263,265], pancreatic cancer [266], brain tumor [267], lung cancer 
[268,269], bladder and kidney cancer [270], cervical cancer [271], and colon 
cancer [263,265-267,269-272].  
The carboxyl (C-) terminal RING domain of UHRF1 confers intrinsic E3 
ligase activity towards histones and non-histone proteins [262,269,273,274]. It 
has been shown that UHRF1 is capable of mediating ubiquitination-dependent 
degradation of the promyelocytic leukemia protein (PML) [274], a tumor 
suppressor protein capable of promoting apoptosis, inhibiting cell proliferation, 
inducing senescence, and suppressing cell migration [275].  Further, a recent 
study reported that UHRF1 ubiquitinates and targets DNMT1 for proteasomal 
degradation through coordinating other DNMT1-associated proteins including 
TIP60 [276].  
Although coexistence of TIP60 and UHRF1 in the same macro-molecular 
protein complex is indicated, direct interaction has not been reported [254,276]. 
Here we have identified UHRF1 as a direct interacting partner of TIP60 and a 
unique negative regulator of the TIP60-p53 interplay. UHRF1 expression induces 
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TIP60 ubiquitination, which does not trigger proteolysis but partially contributes 
to marked suppression of p53 K120 acetylation mediated by TIP60. Ablation of 
UHRF1 promotes K120 acetylation and p53-mediated apoptosis. Through its 
SRA and RING domains UHRF1 binds to TIP60 and severely inhibits TIP60-p53 
interaction, thereby modulating transcription of K120 acetylation-dependent and - 
independent p53 targets PUMA and p21. These data reveal that UHRF1 
negatively regulates TIP60 and modulates TIP60 function in the p53 response 




Figure 15.  Schematic representation of UHRF1 domain structure 
UHRF1 possesses multiple protein modalities. NIRF_N: ubiquitin-like domain; 
TTD: tandem tudor domain; PHD: plant homeo domain; SRA: set and ring 








3.2.1. UHRF1 interacts with TIP60 both in vitro and in vivo 
Recent studies demonstrated correlation of UHRF1 overexpression with tumor 
growth and aggressiveness and poor prognosis in prostate cancer and colorectal 
cancer [277,278]. The oncogenic role of UHRF1 has long been implicated 
through epigenetic regulation, however recent indication of coexistence of 
UHRF1 in the same multi-protein complex with the TIP60 acetyltransferase 
[254,276] that modulates p53- dependent growth arrest and apoptosis leads to the 
attractive hypothesis that UHRF1 may be linked to the TIP60-p53 interplay and 
modulate the p53-dependent damage response pathway. 
We first sought to confirm interaction between UHRF1 and TIP60 by 
performing coimmunoprecipitation experiments in H1299 p53 null lung 
carcinoma cells transfected with FLAG-Tip60 and HA-UHRF1 expression 
vectors. Cell extracts were subjected to immunoprecipitation with M2/FLAG 
antibody. Western blot analysis of M2 eluates revealed that TIP60 was effectively 
precipitated and that UHRF1 is readily detected in TIP60-associated 
immunoprecipitates (Fig. 16A). To further elucidate this interaction under 
physiological settings, we made use of a 3xFLAG-tagged TIP60 knock-in 
HCT116 colon carcinoma cell line. As expected, these cells express endogenous 
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3xFLAG-TIP60 protein that can be specifically recognized by α-FLAG antibody, 
and the level of UHRF1 protein expressed is comparable to that in control 
HCT116 cells (Fig. 16B, lanes 1 and 2). When we subjected extracts from TIP60 
knock-in cells or control HCT116 cells to immunoprecipitation with M2/FLAG 
antibody, TIP60 was specifically immunoprecipitated from the knock-in cells; 
more importantly UHRF1 is easily detected in the immunoprecipitates obtained 
from the knock-in cells but not the control cells (Fig. 16B, lane 2 vs. lane 1), 
suggesting that UHRF1 interacts with TIP60 endogenously. Inversely, extracts 
from U2OS osteosarcoma cells were immunoprecipitated with the α-UHRF1 
antibody or with the control IgG. As expected, endogenous UHRF1 of ~95 kD 
was specifically immunoprecipitated with the α-UHRF1 antibody; more 
importantly, TIP60 is readily detected in the immunoprecipitates obtained with 
the α-UHRF1 antibody but not the control IgG (Fig. 16C, lanes 2 and 3). Thus, 





Figure 16. UHRF1 coimmunoprecipitates with TIP60 exogenously and 
endogenously 
(A) UHRF1 coimmunoprecipitates with TIP60 in an overexpression system. 
Whole cell extracts or immunoprecipitates with M2/FLAG antibody from 
H1299 cells transiently transfected with plasmid DNA expressing HA-
UHRF1 or/and FLAG Tip60 were subjected to Western blot with α-
FLAG and α-HA antibodies. 
(B) UHRF1 interacts with TIP60 endogenously in 3xFLAG-TIP60 knock-in 
cells. Whole cell extracts or M2/FLAG immunoprecipitates from control 
HCT116 cells or HCT116 3xFLAG-Tip60 knock-in cells  were subjected 
to Western blot with α-UHRF1 and α-FLAG antibodies.  
(C) TIP60 interacts with UHRF1 endogenously in U2OS cells. U2OS-derived 
nuclear extracts or immunoprecipitates with a control IgG or α-UHRF1 
antibody were subjected to Western blot with α-TIP60 and α-UHRF1 
antibodies. 










An in vitro GST-pulldown assay was performed to further assess direct 
interaction. Purified GST or GST-tagged TIP60 protein was incubated with in 
vitro translated 
35
S-methione labeled FLAG-UHRF1 protein. Following capture 
with GST resins and recovery of immobilized complexes, the eluted complexes 
were resolved by SDS-PAGE and analyzed by autoradiography. 
35
S-UHRF1 
strongly bound immobilized GST-TIP60, but not GST alone (Fig. 17), 
demonstrating direct UHRF1-TIP60 binding in vitro. Taken together, these data 




Figure 17. UHRF1 interacts with TIP60 directly in vitro 
In vitro translated 
35
S-methione labelled 3xFLAG-UHRF1 protein was 
incubated with purified GST-TIP60 or GST alone. Complexes 
immobilized with GST resins and recovered using reduced glutathione 
were subjected to SDS-PAGE and analyzed by autoradiography. The 
levels of purified GST- TIP60 and GST are shown in the bottom panel 





3.2.2 UHRF1 induces degradation-independent ubiquitination of TIP60 
The C-terminal RING domain endows UHRF1 with intrinsic E3 ubiquitin 
ligase activity. Recent studies have identified PML (promyelocytic leukemia 
protein) and DNMT1 to be substrates for UHRF1-mediated ubiquitin-dependent 
proteolysis [274,276]. We therefore first tested the possibility of UHRF1-
mediated Tip60 ubiquitination.  
To test this hypothesis, a cell-based ubiquitination assay was performed where 
H1299 cells were transfected with expression vectors for FLAG-Tip60 and His-
ubiquitin alone or in combination with HA-UHRF1. Ubiquitinated proteins were 
captured with nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography and 
analyzed by Western blot. Immunoblotting with α-FLAG antibody revealed that 
coexpression of UHRF1 and TIP60 produced significant levels of ubiquitinated 




Figure 18. UHRF1 promotes ubiquitination of TIP60 
UHRF1 induces ubiquitination of TIP60 in vivo. H1299 cells were cotransfected 
with expression vectors encoding FLAG-Tip60 or/and HA-UHRF1 in 
combination with His-ubiquitin. Whole cell extracts and Ni-NTA affinity-purified 
fractions were analyzed by Western blot with α-FLAG and α-HA antibodies. GFP 






To confirm that UHRF1 induces TIP60 ubiquitination through its E3 ubiquitin 
ligase activity, we further made use of C724A UHRF1, a RING finger point 
mutant that retains TIP60 binding affinity (Fig. 19A) but was previously reported 
deficient in in vitro autoubiquitination [269]. In a cell-based ubiquitination assay, 
wild-type UHRF1 displays robust autoubiquitination while the C724A UHRF1 
mutant lack E3 ligase activity (Fig. 19B, middle panel, lane 3 vs. lane 4). More 
importantly, coexpression of wild-type UHRF1 strongly induced TIP60 
ubiquitination, while in the absence of UHRF1 E3 ligase activity TIP60 
ubiquitination was undetectable (Fig. 19B, upper panel, lane 3 vs. lane 4).  
Together these data demonstrate that UHRF1 induces TIP60 ubiquitination 




Figure 19. UHRF1 induces TIP60 ubiquitination directly through its E3 
ligase activity 
(A) C724A UHRF1 mutant retains interaction with TIP60. H1299 were 
transiently transfected with FLAG-Tip60 in combination with Myc-
UHRF1 or Myc-C724A UHRF1. Whole cell extracts or 
immunoprecipitates with M2/FLAG antibody were analyzed by Western 
blot with α-MYC and α-FLAG antibodies.  
(B) UHRF1 directly ubiquitinates TIP60 through its E3 ubiquitin ligase 
activity. H1299 cells were cotransfected with FLAG-Tip60 and His-
ubiquitin alone or together with either HA-UHRF1 or HA-C724A UHRF1 
expression vectors. Whole cell extracts and Ni-NTA affinity purified 
fractions were analyzed by Western blot with α-FLAG and α-HA 
antibodies. GFP was used as control to confirm equal transfection. 




Because ubiquitination is most frequently associated with proteosomal 
degradation, we sought to test whether UHRF1 promotes Tip60 degradation. To 
this end, H1299 cells were transfected with FLAG-HA-Tip60 in combination of 
increasing amounts of HA-UHRF1 expression vector. Western blot analysis of 
total cell extracts revealed that exogenous TIP60 protein levels remain unchanged 
in the presence of increasing levels of UHRF1 (Fig. 20A). To further confirm that 
UHRF1 is incapable of regulating Tip60 stability, we inactivated endogenous 
UHRF1 in 3xFLAG-TIP60 knock-in HCT116 cells.  Following two rounds of 
transfection with either the control siRNA or UHRF1-specific siRNA, total cell 
extracts were analyzed by Western blot and untreated parental HCT116 was used 
as a control to confirm expression of 3xFLAG tagged TIP60. As expected, the 
level of endogenous UHRF1 protein was severely ablated after transfection with 
UHRF1-RNAi (Fig. 20B, lane 2 vs. lane 1). More importantly, TIP60 protein 
level was unaffected by UHRF1 ablation (Fig. 20B, lanes 1 and 2 vs. lane 3), 
suggesting that UHRF1 does not regulate TIP60 protein stability. Furthermore, we 
assessed Tip60 mRNA level in HCT116 cells that were transfected with UHRF1-
specific siRNA oligos or a control siRNA oligo. Quantitative real time PCR 
analysis reveals that the level of Tip60 mRNA remains unaffected by UHRF1 
ablation (Fig. 20C). Taken together, these data suggest that UHRF1 does not 




Figure 20. UHRF1 does not promote TIP60 degradation or affect Tip60 at 
the transcription level 
(A) UHRF1 expression does not induce TIP60 degradation. H1299 cells were 
transfected with FLAG-HA-Tip60 in combination with increasing levels 
of HA-UHRF1. Whole cell extracts were analyzed by Western blot with 
α-HA antibody. 
(B) UHRF1 depletion does not affect TIP60 protein level. HCT116 cells were 
treated with 2 rounds of knock-down with either control RNAi, UHRF1 
RNAi, or TIP60 RNAi. Whole cell extracts were analyzed by Western blot 
with α-UHRF1 and α- TIP60 antibodies.  
(C) UHRF1 depletion does not affect Tip60 mRNA level. Total RNA was 
extracted from control RNAi or UHRF1 RNAi treated HCT116. 
Following reverse transcription, the abundance of Tip60 mRNA was 
assessed using quatitative real time PCR. 
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Our finding that the TIP60-conjugated polyubiquitin chains generated by 
UHRF1 do not serve as a targeting signal for proteolysis predicts that they may 
not be of the typical K48-linked ubiquitin chains. Chains that conjugate through 
K63 of ubiquitin, for example, have been reported to involve protein trafficking or 
DNA repair [279,280]. In a cell-based ubiquitination assay performed with either 
wild-type ubiquitin (WT-Ub), mutant ubiquitin with arginine (R) replacing 
specific lysine sites (KR-Ub), or a mutant ubiquitin with all lysines replaced (K0-
Ub) (Fig. 21A), TIP60 ubiquitination was retained in the presence of K48R-Ub. 
In contrast, K27R-Ub diminished TIP60 ubiquitination level to almost that 
obtained with K0-Ub; K6R-, K29R- or K63R-Ub also attenuated TIP60 
ubiquitination to different extents (Fig. 21A). Conversely, by utilizing mutant 
ubiquitin containing only one unaltered lysine (K-Ub) in the same assay, K27-Ub 
was most readily incorporated by UHRF1, and K6-, K29-, and K63 ubiquitin 
could all be incorporated to a lesser extent (Fig. 21B). Together these data 
confirm that K48-dependent linkage, which is characteristic of ubiquitin-mediated 
proteolysis, is excluded and suggest that TIP60 ubiquitination by UHRF1 relies 
on K27 as a major site for conjugation but likely involves a combination of K6, 




Figure 21. UHRF1 ubiquitinates TIP60 through atypical ubiquitin lysine 
linkages 
(A and B) UHRF1 mediates K48-independent polyubiquitin chain conjugation on 
TIP60. H1299 cells were cotransfected with expression vectors for FLAG-HA-
Tip60 and HA-UHRF1, in combination with His/HA double tagged ubiquitin 
mutants. Ni-NTA purified fractions were immunoblotted with α-FLAG antibody; 
whole cell lysates were immunoblotted with α-HA and α-FLAG antibodies. GFP 













3.2.3 UHRF1 depletion increases TIP60-mediated p53 acetylation at K120 
and enhances apoptosis 
Because TIP60 is a known regulator of p53 acetylation at the K120 residue, 
we first assessed whether UHRF1 modulates TIP60-dependent acetylation of p53. 
M2/FLAG immunoprecipitation of extracts from H1299 cells transfected with 
FLAG-p53, Tip60, and HA-UHRF1, revealed that p53 is easily acetylated by 
TIP60 and acetylation was markedly attenuated upon UHRF1 expression (Fig. 
22A).  
UHRF1 was further ablated in U2OS cells via RNAi and endogenous p53 
acetylation was assessed by immunoprecipitating cell extracts with the α-Ac-p53-
K120 antibody. Prior to harvesting, cells were subjected to trichostatin A (for 
inhibiting HDAC1/HDAC2-mediated p53 deacetylation) and nicotinamide (for 
inhibiting SIRT1-mediated p53 deacetylation) treatment to enrich acetylated 
endogenous p53. As shown in Fig. 22B, p53 K120 acetylation was readily 
detected with treatment of deacetylase inhibitors, and significantly enhanced upon 
UHRF1 ablation, suggesting that UHRF1 is a potent suppressor of TIP60-




Figure 22. UHRF1 suppresses TIP60-mediated p53 acetylation at K120 
(A) UHRF1 expression inhibits p53 acetylation by TIP60 at K120. H1299 
cells were transiently transfected with plasmid DNA expressing FLAG-
p53, Tip60 and HA-UHRF1. Total cell extracts and M2 
immunoprecipitates were assayed by Western blot using antibodies against 
HA, p53 and p53-AcK120. 
(B) UHRF1 inactivation significantly increases p53 acetylation at K120. 
U2OS cells were transiently transfected with either control siRNA or 
UHRF1 siRNA, and treated for 6 hr with 1µM trichostatin A (TSA) and 
5mM nicotinamde (NTA) prior to harvesting. Cell extracts and 
immunoprecipitates obtained with α-Ac-p53K120 or control IgG were 













The Gu team and others previously demonstrated that p53 K120 acetylation is 
indispensable for apoptosis, leading to our speculation that UHRF1 might 
modulate apoptosis in cells at risk of DNA damage. Apoptosis was therefore 
assessed by flow cytometric analysis of DNA fragmentation in UHRF1-ablated 
U2OS cells treated with etoposide and stained with propidium iodide (PI). As 
shown in Fig. 23A, UHRF1 inactivation minimally affected basal level sub-G1 
content but markedly increased apoptosis following etoposide challenge. 
Quantitative analysis revealed that following 36 or 44 hr of etoposide treatment, 
an average of 10.21% and 21.58% of control RNAi-treated cells were apoptotic, 
whereas a dramatically elevated 26.91% and 34.96% of UHRF1 RNAi-treated 
cells underwent apoptosis (Fig. 23B). Collectively, these data demonstrate that 
UHRF1 negatively regulates damage-induced apoptosis through attenuating 




Figure 23. UHRF1 depletion augments damage-induced apoptosis 
(A) FACS analysis of UHRF1-inactivated U2OS cells treated with etoposide. 
U2OS cells transiently transfected with either control siRNA or UHRF1 
siRNA were treated with 20uM etoposide for the indicated time. Cells 
were subsequently fixed in 80% cold methanol, stained with propidium 
iodide and subjected to DNA content analysis by flow cytometry.  
(B) UHRF1 RNAi increases apoptosis. Apoptosis was assessed as in (A) and 
percentages of apoptotic cells are presented as average values of three 














3.2.4 UHRF1 inhibits TIP60-p53 interaction  
We further assessed UHRF1 regulation of TIP60-p53 interaction by 
transfecting H1299 with increasing amounts of Myc-UHRF1 in the presence of 
p53 and FLAG-Tip60 and subjecting cell extracts to M2/FLAG 
immunoprecipitation. p53 was readily detected in TIP60-associated 
immunoprecipitates; however, upon UHRF1 expression the amount of TIP60-
bound p53 decreased drastically (Fig. 24A), indicating that UHRF1 inhibits TIP60 
interaction with p53.  
Having established that UHRF1 is capable of attenuating the TIP60-p53 
interplay, we next sought to test whether this is achieved through TIP60 
ubiquitination. Coimmunoprecipitation of p53 and TIP60 was performed in 
extracts of H1299 cells transfected with p53, FLAG-Tip60 and Myc-tagged 
UHRF1 or C724A UHRF1. As shown in Fig. 24B, expression of wild-type 
UHRF1 diminished the amount of p53 detected in TIP60-associated 
immunoprecipitates, whereas the ligase activity deficient C724A mutant only 
partially inhibited TIP60 interaction with p53. Furthermore, while wild-type 
UHRF1 completely abolished p53 K120 acetylation by TIP60, the C724A mutant 
mildly diminished p53 acetylation (Fig. 24C). Taken together, these results 
demonstrate that UHRF1 inhibits TIP60-p53 interaction and TIP60-mediated p53 
acetylation, and that UHRF1-induced TIP60 ubiquitination may contribute 
partially to the suppression of the TIP60-p53 interplay. 
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Figure 24. UHRF1 suppresses TIP60-p53 interaction partially through 
promoting TIP60 ubiquitination 
(A) UHRF1 expression inhibits TIP60 interaction with p53. H1299 cells were 
transiently transfected with FLAG-Tip60, p53 and HA-UHRF1 expression 
vectors. Cell extracts and M2 immunoprecipitates were assayed by 
Western blot using α-HA, α-FLAG and α-p53 antibodies.  
(B) Loss of UHRF1-mediated TIP60 ubiquitination partially suppresses TIP60 
interaction with p53. Total cell extracts and M2 immunoprecipitates from 
H1299 transiently transfected with FLAG-Tip60, p53 and Myc-tagged 
UHRF1 or C724A UHRF1 expression vectors were assayed by Western 
blot using antibodies against MYC, FLAG, and p53.  
(C) Loss of UHRF1-mediated TIP60 ubiquitination partially inhibits p53 
acetylation by TIP60 at K120. Total cell extracts and M2 
immunoprecipitates from H1299 transiently transfected with FLAG-p53, 
Tip60 and Myc-tagged UHRF1 or C724A UHRF1 expression vectors 
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3.2.5 SRA and RING domains of UHRF1 are indispensable for UHRF1 
suppression of TIP60-p53 interaction 
The partial suppression of the TIP60-p53 interplay by the ligase activity 
deficient UHRF1 mutant suggests that UHRF1 may elicit inhibitory effects 
through mechanisms including but not limited to TIP60 ubiquitination. It would 
therefore be interesting to elucidate what other functional domains might be 
responsible for exerting the inhibition. To this end, we generated a series of Myc-
tagged UHRF1 truncation mutants as diagrammed in Fig. 25A with deletion of 
one or more functional domains.  
UHRF1-TIP60 interaction was determined by transfecting H1299 with F-
Tip60 and Myc-tagged mutant UHRF1, followed by Western blot analysis of 
M2/FLAG immunoprecipitates. Mutant UHRF1 lacking the N-terminal ubiquitin-
like domain (ΔNIRF), the Plant Homeo domain (ΔPHD), or the truncation mutant 
possessing only the SRA (Set and Ring Associated) and RING domains (S+R) 
bound strongly to TIP60 (Fig. 25B, lanes 3, 6, and 7); mutant UHRF1 that lacked 
either the SRA domain (ΔSRA) or the RING domain (ΔRING) showed weaker 
interaction with TIP60 (Fig. 25B, lanes 4 and 8); whereas loss of both SRA and 
RING domains (ΔS+R) completely abolished TIP60 interaction (Fig. 25B, lane 5), 
indicating that the SRA and RING domains are indispensable for UHRF1 
interaction with TIP60. 
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Figure 25. The SRA and RING domains of UHRF1 confer interaction with 
TIP60 
(A) Schematic representation of UHRF1 deletion mutants used in interaction 
domain mapping. Full-length UHRF1 and all deletion mutants were 
subcloned into pCMV-Myc expression vector.  
(B) UHRF1 interacts with TIP60 through its SRA and RING domains. H1299 
cells were transiently transfected with expression vectors for FLAG-Tip60 
and MYC-tagged UHRF1 deletion contructs. Total cell extracts and M2 
immunoprecipitates were assayed by Western blot using antibodies against 











To test whether the inhibition of TIP60-p53 interaction requires UHRF1 
affinity for TIP60, coimmunoprecipitation of p53 with TIP60 was performed in 
extracts of H1299 cells transfected with p53, FLAG-Tip60, and Myc-UHRF1 or 
Myc-ΔS+R UHRF1. As expected, Western blot analysis of M2/FLAG eluates 
revealed that the level of TIP60-associated p53 was severely ablated upon 
UHRF1 expression (Fig. 26A, lane 3 vs. lane 2). Strikingly, the ΔS+R mutant, 
which lacks binding affinity or TIP60, was incapable of suppressing TIP60-p53 
interaction (Fig. 26A, lane 4 vs. lane 2).  
In an effort to test whether p53 K120 acetylation is affected by loss of 
UHRF1-TIP60 interaction, the level of K120 acetylation was assessed by 
M2/FLAG immunoprecipitation of total p53 from H1299 cells transfected with 
FLAG-p53, Tip60, and Myc-UHRF1 or Myc-ΔS+R UHRF1 expression vectors 
and immunoblotting with α-Ac-p53K120 antibodies. Consistent with Fig. 24C, 
wild-type UHRF1 significantly diminished p53 acetylation by TIP60 (Fig. 26B, 
lane 2 and lane 3). However the ΔS+R mutant completely lost inhibition of p53 




Figure 26. The SRA and RING domains of UHRF1 are indispensable for 
inhibition of TIP60-p53 interaction and p53 acetylation 
(A)  The SRA and RING domains of UHRF1 are indispensable for inhibition 
of TIP60-p53 interaction. Total cell extracts and M2 immunoprecipitate 
from H1299 transiently transfected with FLAG-Tip60, p53 and Myc-
tagged full-length UHRF1 or ΔS+R UHRF1 expression vectors were 
analyzed by Western blot using antibodies against MYC, FLAG, and p53. 
(B) The UHRF1ΔSRA+RING mutant loses inhibition of TIP60-mediated p53 
acetylation at K120. Total cell extracts and M2 immunoprecipitates from 
H1299 transiently transfected with FLAG-p53, Tip60 and MYC-tagged 
full-length UHRF1 or ΔS+R UHRF1 expression vectors were analyzed by 
Western blot using α-Myc, α- TIP60, α-p53 and α-Acp53K120 antibodies. 









We then sought to validate that the loss of TIP60 affinity is conferred through 
the deletion of SRA and RING domains rather than altered protein localization. 
Therefore cellular localization of full-length and mutant UHRF1 was assessed by 
immunostaining Myc-UHRF1 or Myc-ΔS+R UHRF1 transfected U2OS cells. Co-
staining with the α-Myc antibody and the nuclei labeling reagent 4,6-diamidino-2-
phenylindole (DAPI) demonstrated that both the full-length UHRF1 protein and 
the ΔS+R mutant localize to the nucleus (Fig. 27). These data collectively suggest 
that UHRF1 inhibits TIP60-p53 interaction through competitively binding to 
TIP60 via its SRA and RING domains, and ablation of UHRF1-TIP60 binding 




Figure 27. The UHRF1ΔSRA+RING mutant retains nuclear localization 
The UHRF1ΔSRA+RING mutant retains nuclear localization. U2OS cells were 
transiently transfected with expression vectors for Myc-tagged full-length UHRF1 
or ΔS+R UHRF1. 24h posttransfection, cells were fixed with paraformaldehyde, 
immunostained with α-Myc antibody and counterstained with 4,6-diamidino-2-







                             




3.2.6  UHRF1 depletion upregulates activation of PUMA and p21 but not 
HDM2 
Previous studies demonstrate that apart from promoting p53 acetylation at the 
K120 site, which is specifically required for the activation of apoptotic targets, 
TIP60 also regulates p53 transcription of p21 in the absence of K120 acetylation, 
through p53-dependent recruitment to the p21 promoter and modulation of 
histone H4 acetylation [201]. In contrast, TIP60 is not recruited to the HDM2 
promoter and activation of the p53 feedback target HDM2 is not dependent on 
TIP60 [201]. Therefore our finding that UHRF1 inhibits not only p53 acetylation 
but also TIP60-p53 interaction predicts that UHRF1 ablation should result in 
increased activation of both PUMA and p21 in response to DNA damage because 
an increased amount of TIP60 now becomes available for promoter co-
recruitment and/or co-activation of p53. Conversely, HDM2 induction by p53, 
which is independent of TIP60, should remain unaffected regardless of UHRF1 
status.  
To test this hypothesis, we performed RNAi-mediated inactivation of UHRF1 
in HCT116 cells followed by treatment with the 5-fluorouracil (5-FU) 
antimetabolite that strongly activates p53 and induces p53-dependent growth 
arrest and apoptosis in HCT116 [281]. As expected, upon 5-FU treatment p53 
levels increased drastically; and notably UHRF1 inactivation affected neither 
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basal p53 level (Fig. 28A, lane 6 vs. lane 1) nor the accumulation of p53 protein. 
Furthermore, at all time points assessed, HDM2 induction was unaffected by 
UHRF1 depletion but PUMA and p21 activation was significantly increased in 
the UHRF1-depleted group (Fig. 28A, lanes 7-10 vs. lanes 2-5).  
To exclude off-target effects of RNAi and validate that our finding was not 
specific to HCT116 cells or the 5-FU drug, we ablated UHRF1 in U2OS using 
three siRNA oligos targeting different regions of the UHRF1 mRNA, and further 
treated these cells with another DNA damage reagent doxorubicin. UHRF1 was 
effectively ablated by all three siRNA oligos and doxorubicin-induced HDM2 
induction remain unaffected by UHRF1 depletion, however PUMA and p21 
activation was significantly increased by UHRF1 ablation using all three oligos 





Figure 28. UHRF1 depletion upregulates activation of PUMA and p21 but 
not HDM2 following DNA damage 
(A) UHRF1 RNAi in HCT116 cells upregulates 5-FU induced PUMA and 
p21 activation but not HDM2 activation. HCT1116 cells were treated 
with 2 rounds of knock-down with either control RNAi or UHRF1 
RNAi. Following treatment with 400μM 5-FU for the indicated time, 
whole cell extracts were analyzed by Western blot with the indicated 
antibodies.      
(B) UHRF1 RNAi upregulates doxorubicin induced PUMA and p21 but 
not MDM2 activation in U2OS cells. U2OS cells were transiently 
transfected with control siRNA or three different U2OS-specific 
siRNA oligos and treated with or without 0.5μM doxorubicin for 16 hr. 













We further confirmed that UHRF1 ablation affected p53-dependent 
transcription of PUMA and p21 but not HDM2 by examining the mRNA levels of 
these targets using qRT-PCR (Fig. 29). Indeed, basal HDM2, PUMA and p21 
mRNA levels were unaffected by UHRF1 depletion. Upon 5-FU treatment, 
PUMA and p21 transcription was considerably augmented following UHRF1-
RNAi, whereas HDM2 mRNA level increased upon 5-FU treatment and remained 
unaffected in the UHRF1-RNAi treated group (Fig. 29). mRNA levels of other 
p53 apoptotic targets such as BAX, PIG3, and NOXA were also assessed; and 
UHRF1 ablation augmented the mRNA induction of these targets, especially at 
later time points (Fig. 29). These data confirm that UHRF1 antagonizes p53-
dependent transcription of growth arrest and apoptotic targets, but not the HDM2 
feedback target.  
Together, these data validate UHRF1 ablation does not affect p53-mediated 





Figure 29. UHRF1 RNAi upregulates 5-FU induced growth arrest and 
apoptotic target transcription but not HDM2 transcription 
HCT116 were treated with 400μM 5-FU for the indicated time following control 
RNAi or UHRF1 RNAi. Total RNA was extracted and cDNA was prepared by 
reverse transcription. mRNA abundance for the indicated genes assessed using 




To verify that the effect of UHRF1 on PUMA and p21 activation is p53- 




pair prior to 5-FU 
treatment. Following damage, p53 accumulated in p53
+/+
 HCT116 and PUMA 
and p21 were activated, the extent to which were significantly increased by 
UHRF1 depletion (Fig. 30A, lanes 1-4). In a p53-deficient background 5-FU 
failed to activate PUMA and p21; and UHRF1 ablation did not increase PUMA 
and p21 level upon 5-FU treatment in the absence of p53 (Fig. 30A, lanes 5-8). 5-
FU induced HDM2 only in the presence of p53, and no difference in HDM2 
activation was observed upon UHRF1 RNAi.  
Alternatively, p53-dependency was confirmed in U2OS by double 
inactivation of UHRF1 and p53 followed by doxorubicin treatment (Fig. 30B). 
Inactivating UHRF1 alone strongly increased doxorubicin-induced PUMA and 
p21 activation, when combined with p53 depletion UHRF1 ablation could not 
affect PUMA and p21 levels before and after damage, suggesting that the effect of 




Figure 30. UHRF1 modulation of damage-induced PUMA and p21 activation 
in a p53-dependent manner 
(A)  p53 dependency in HCT pair. UHRF1 is inactivated by RNAi in either 
p53+/+ or p53-/- HCT116 cells. Subsequently, cells were treated with or 
without 400μM 5-FU for 8 hr before extraction and Western blot analysis 
using the indicated antibodies. 
(B) p53 dependency using double knocking down in U2OS. UHRF1 alone, or 
both p53 and UHRF1 were ablated in U2OS cells using RNAi. 
Subsequently, cells were treated with or without 1µM doxorubicin for 16 













To further validate that these effects are also dependent on TIP60, we 
inactivated UHRF1 or TIP60 alone, or in combination in U2OS cells using RNAi. 
p53 levels accumulated and HDM2 was activated normally following doxorubicin 
treatment in samples that were depleted of either UHRF1, TIP60 or both. 
However the induction of PUMA and p21 expression was severely diminished by 
TIP60 ablation (Fig. 31, lanes 5 and 6); and more importantly, in the TIP60-
deficient background UHRF1 depletion displayed no effect on PUMA and p21 




Figure 31. UHRF1 modulates damage-induced PUMA and p21 activation in 
a TIP60-dependent manner 
UHRF1 or TIP60 alone, or both UHRF1 and TIP60 were inactivated in U2OS 
using RNAi. Subsequently, cells were subjected to 16 hr 0.5μM doxorubicin 








Because UHRF1 ablation increases p53-mediated damage-induced p21 
expression, the physiological role of UHRF1 in regulating p53-mediated cell 
growth arrest was also tested. To this end, the effect of UHRF1 ablation on cell 
growth was examined by monitoring BrdU incorporation, a marker for 
proliferating cells, following etoposide treatment. U2OS cells were transfected 
with either control siRNA or UHRF1 siRNA prior to treatment with etoposide. 
Following 16 or 24 hr of etoposide treatment, these cells were then labeled for 1 
hr with BrdU, fixed in paraformaldehyde and double stained with the α-BrdU 
antibody and 4,6-diamidino-2-phenylindole (DAPI). As shown in Fig. 32, at 0 
timepoint, U2OS cells transfected with UHRF1 siRNA showed a similar level of 
BrdU incorporation (~50%) compared to cells transfected with control siRNA. In 
contrast, following 16 or 24 hr of etoposide treatment, only 24.37% and 16.5% of 
cells transfected with UHRF1 siRNA were detected BrdU-positive, whereas 44.74% 
and 31.23% of cells transfected with control siRNA were BrdU-positive. These 
data validate that UHRF1 negatively regulates p53-mediated growth arrest. 
Together our data suggest that UHRF1 modulates p53 activity through 
negatively regulating TIP60-mediated functions in both K120 acetylation-





Figure 32. UHRF1 depletion upregulates damage-induced growth arrest 
(A) BrdU incorporation of UHRF1-inactivated U2OS cells treated with 
etoposide. U2OS cells were transiently transfected with either control 
siRNA or UHRF1 siRNA. 72 hr post-transfection, cells were treated 1 hr 
with 10µM BrdU and immunostained with the α-BrdU antibody. The 
nuclei are in blue (DAPI), and BrdU-positive nuclei are shown in red.  
(B) UHRF1 RNAi decreases cel proliferation. BrdU positive cells in (A) were 
counted in 6-8 microscopic fields and percentages of BrdU positive cells 
are presented as average values from 3 independent experiments. Error 














Our findings identify that UHRF1 is a direct interacting partner of TIP60 and 
a potent negative regulator of the TIP60-p53 interplay. UHRF1 expression 
induces degradation-independent ubiquitination of TIP60, which partially 
contributes to the marked suppression of TIP60-mediated p53 acetylation at K120. 
In contrast, UHRF1 ablation significantly increases p53 K120 acetylation, upon 
which p53-mediated apoptosis is dependent. Further elucidating the underlying 
mechanism, we found that UHRF1 severely inhibits TIP60 interaction with p53, 
leading to UHRF1 modulation of TIP60 function both dependent and independent 
of its ability to acetylate p53 at K120. Upon DNA damage, UHRF1 inactivation 
augments PUMA and p21 transcription, both of which rely on TIP60 but are 
differentially dependent on p53 K120 acetylation; in contrast, UHRF1 depletion 
does not affect stressed induced HDM2 transcription by p53, which is 
independent of TIP60 status. Therefore, our findings suggest that UHRF1 acts as 
a critical negative regulator of TIP60 upstream of the p53 pathway, thereby 
negatively regulating TIP60-dependent transcription of key targets involved in 
growth arrest and apoptosis in cells at risk of DNA damage.  
Based on our observation, we propose a model of tumorigenesis and/or tumor 
progression in the presence of high levels of cellular UHRF1 (Fig. 33). In normal 
cells, p53 is stabilized and activated upon DNA damage and induces transcription 
of the HDM2 feedback regulator in the absence of TIP60 recruitment and histone 
128 
 
H4 acetylation in the vicinity of the HDM2 promoter. TIP60-p53 interaction is 
required for TIP60 recruitment to p53 target promoters and the induction of 
histone H4 acetylation, leading to p21 transactivation and growth arrest. Finally in 
cells that have undergone excessive damage, TIP60 acetylates p53 at K120, 
resulting in induction of PUMA and activation of the irreversible apoptotic 
pathway, thereby maintaining cellular and genomic stability and suppressing 
tumorigenesis (Fig. 33A). In contrast, UHRF1 overexpression leads to excessive 
UHRF1-TIP60 interaction and sequestration of TIP60 from associating with p53. 
This suppresses stress-induced TIP60 recruitment to p53 target promoters, 
acetylation of histone H4, and p53 actylation at K120. As a result, p53-dependent 
p21 and PUMA transactivation are abolished, and proprogation of the damaged 




Figure 33. A model for tumorigenesis/tumor progression in cells with UHRF1 
overexpression 














TIP60 is a haplo-insufficient tumor suppressor with well-documented 
functions in regulating transcription, DNA damage repair, and p53-mediated 
growth arrest and apoptosis [282]. Therefore TIP60 function should require tight 
regulation, which to date has been shown achievable through post-translational 
modification or protein-protein interaction. Post-translationally, phosphorylation 
and autoacetylation of TIP60 upon DNA damage are required for TIP60 HAT 
activity and p53-mediated apoptosis [227,283,284]; whereas the E3 ligases 
HDM2 and CUL3 have been reported to target TIP60 directly for ubiquitin-
dependent proteolysis [285,286]. With regards to protein-protein interaction, a 
few studies have implicated that interaction with viral transforming proteins 
attenuates TIP60 HAT activity, de-stabilizes TIP60, or abrogates p53- dependent 
apoptosis [226,287]. Recently, we have identified the p90 protein (also known as 
CCDC8) to specifically enhance p53-dependent apoptotic response through 
binding to TIP60 and promoting TIP60-mediated p53 acetylation [288]. Our 
current study identifies UHRF1 to be another upstream regulator but functions to 
repress p53-dependent damage response through binding to TIP60, inhibiting 
TIP60-p53 interaction and TIP60-mediated p53 acetylation. Thus p90 and 
UHRF1, while both regulating upstream of TIP60 through protein-protein 
interaction, controls p53 function via distinct and opposing mechanisms. 
At present, it is unclear how UHRF1 binding to TIP60 releases p53 from 
TIP60 interaction and renders TIP60 inactive in acetylating p53. TIP60 comprises 
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an N-terminal chromodomain and a catalytic MYST domain. It is possible that 
UHRF1 and p53 compete for the same binding site within TIP60, or that UHRF1 
binding induces a conformation change that makes TIP60 inaccessible for p53 
binding. Further mapping of UHRF1-TIP60 and TIP60-p53 interaction domains 
and structural analysis of binding pockets may shed light in this respect. In 
addition to directly inhibiting TIP60-p53 binding, UHRF1 may change TIP60 
conformation to compromise its HAT activity towards p53 and histone H4, the 
acetylation of which is required on p21 and PUMA promoters but not HDM2 
promoter for transcription activation of respective gene targets [201].  
Our results also reveal a previously unrecognized mechanism of TIP60 
regulation through degradation-independent ubiquitination. Two previous studies 
report regulation of TIP60 stability by E3 ubiquitin ligases [285,286], which 
likely contribute to maintenance of low TIP60 protein level in the absence of 
damage. Here we show that UHRF1 mediates TIP60 ubiquitination, which does 
not affect protein stability but rather negatively regulates TIP60-p53 interaction 
and TIP60 acetyltransferase activity. Although ectopic expression of E3 ligase-
deficient mutant UHRF1 mildly suppresses the TIP60-p53 interplay, this could be 
owing to limited amount of cellular TIP60 being ubiquitinated by UHRF1. While 
physiological functions of degradation independent ubiquitination are not entirely 
understood, there have been a few studies implicating signal transduction, 
recruitment of interacting partners and regulation of enzymatic activities [289]. 
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That ubiquitinated TIP60 loses acetyltransferase activity as suggested by our data 
is an interesting hypothesis and needs to be investigated further. It is also possible 
that UHRF1-mediated ubiquitination of TIP60 decreases its affinity for p53 or 
compromises recruitment to chromatin.  
Overexpression of UHRF1 is found in a wide array of human tumors, 
including breast cancer, pancreatic cancer, brain tumor, lung cancer, bladder and 
kidney cancer, cervical cancer, and colon cancer [263,265-267,269-271]. 
Recently UHRF1 overexpression has been linked to tumor progression and poor 
prognosis in prostate cancer and colorectal cancer [277,278]. UHRF1 function in 
heterochromatin formation and inheritance of genomic DNA methylation patterns 
has long been implicated as its major oncogenic role. A number of anticancer 
drugs have been developed to target UHRF1 complex members such as HDAC1 
and DNMT1 [270,290], both of which are upregulated in tumors [255,291-296]. 
However, the presence of multiple members of the HDAC family and the 
ubiquitous basal expression of HDACs and DNMT1 in normal cells create 
significant challenge for high specificity and low side effect [270,296]. In contrast 
to HDAC1 and DNMT1, the basal expression of UHRF1 in normal tissues is 
significantly lower and almost non-detectable in differentiated tissues [255,297], 
making UHRF1 a very attractive therapeutic target and suggests that UHRF1 
inhibitors, if available, could have fewer side effects than current drugs.  
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Our study suggests that apart from epigenetic regulation, the oncogenic 
functions of UHRF1 may also be conferred through inhibition of the TIP60-p53 
interplay and p53-dependent damage-induced apoptosis and growth arrest. It will 
be interesting to test whether UHRF1 overexpression and p53 mutation are 
mutually exclusive in human tumors, and in tumors with wild-type p53 whether 
downregulation of UHRF1 or treatment with small molecule inhibitors targeting 
UHRF1-TIP60 interaction would de-repress the TIP60-p53 interplay and 





3.4 Materials and methods 
Plasmids  
All UHRF1 expression vectors were constructed by PCR amplification from a 
pET28a-UHRF1 expression vector that was generously gifted from Dr. Zhenghe 
Wang at Case Western Reserve University. UHRF1 was subcloned into either the 
pCMV-Myc-N or pCMV-HA expression vectors (Clontech). The 3xFLAG-
UHRF1 construct used for in vitro translation is also a gift from Dr. Zhenghe 
Wang. Deletion mutants of UHRF1 were further constructed by PCR 
amplification from the full length expression plasmids and subcloning into 
respective vectors. Point mutants of UHRF1 were introduced using the 
Quikchange site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s protocol. 
Cell culture 
H1299 and U2OS cells were maintained in DMEM (Cellgro) and HCT116 
cells in McCoy’s 5A medium (Cellgro). All media were supplemented with 10% 
fetal bovine serum (Gibco), 100 I.U./mL penicillin and  100 ug/mL streptomycin 
(Cellgro). Transfections with plasmid DNA and siRNA were performed using 




Antibodies used in this study include UHRF1 (H-65 and H-8), p53 (DO-1), 
p21 (SX118), PUMA (H-136), TIGAR (E-2) and Myc (9E10) from Santa Cruz, β-
actin (AC-15) and Flag (M2) from Sigma, MDM2 (Ab-5) from EMD Biosciences, 
HA (3F10) from Roche Applied Science, GFP (JL-8) from Clontech, and α-Ac-
p53K120 antibody [201]. α-TIP60 (CLHF) antibody was a generous gift from Dr. 
Bruno Amati at European Institute of Oncology.  
Western blot and immunoprecipitation 
For Western blot analysis, cells were lysed in cold RIPA buffer (20mM Tris-
HCl, pH8.0, 150mM NaCl, 1% Triton-X100, 1% DOC, 1mM EDTA, 0.05% SDS 
and freshly supplemented protease inhibitor cocktail).  
Co-immunoprecipitation assays were performed as decribed previously (Dai 
et al., 2011). In brief, cells were lysed in cold BC100 bufffer (20mM Tris-HCl, 
pH7.9, 100mM NaCl, 10% glycerol, 0.2mM EDTA, 0.2% Triton X-100 and 
freshly supplemented protease inhibitor) with mild sonication. 5% of cell extracts 
were saved for input, and the rest was first pre-cleared with A/G PLUS agarose 
beads (Santa Cruz Biotechnology) at 4ºC with rotation, then incubated with the 
antibody or control IgG at 4ºC overnight. A/G PLUS agarose beads were then 
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added for 3 hr incubation at 4ºC. After five washes with the lysis buffer, the 
bound proteins were eluted by boiling with SDS sample buffer.  
For immunoprecipitation of ectopically expressed FLAG-tagged proteins, 
cells were lysed in Flag lysis buffer (50mM Tris-HCl, pH7.9, 137mM NaCl, 
10mM NaF, 1mM EDTA, 1% Triton X-100, 0.2% sarkosyl, 10% glycerol and 
freshly supplemented protease inhibitor). When detection of acetylated proteins 
was desired, lysis buffer was freshly supplemented with 2µM trichostatin A and 
10mM nicotinamide. Cell extracts were incubated with the monoclonal M2/FLAG 
agarose beads (Sigma) at 4ºC overnight. After five washes with the lysis buffer, 
the bound proteins were eluted with FLAG-peptide (Sigma) in BC100 for 2 hr at 
4ºC. 
siRNA-mediated Ablation of UHRF1, TIP60 and p53 
Ablation of UHRF1 was performed by transfection of HCT116 cells or U2OS 
cells with siRNA duplex oligonucleotides (Silencer Select S26553, S26554, 
S26555) synthesized by Ambion. Ablation of TIP60 was performed by 
transfection with a siRNA duplex: 5’-ACGGAAGGUGGAGGUGGUUdTdT-3’ 
and 5’-AACCACCUCCACCUUCCGUdTdT-3’ synthesized by Dharmacon. 
Ablation of p53 was performed by transfection with siRNA duplex oligoset (On-
Target-Plus Smartpool L00332900, Dharmacon). Control siRNA (On-Target-Plus 
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siControl nontargeting pool D00181010, Dharmacon) was also used for 
transfection.  
RNAi transfections were performed 2 times in HCT116 cells and 3 times in 
U2OS cells with Lipofectamine2000 according to the manufacturer’s protocol 
(Invitrogen). 
Apoptosis 
Apoptosis was measured by FACs analysis of DNA content. After treatment 
with DNA damage reagents for the indicated time, dead and live cells were 
collected by mild trypsinization, washed with PBS, fixed in cold 80% methanol, 
and stored at -20ºC until stained. After fixation, cells were washed twice with cold 
PBS and incubated 20 min at room temperature with 50µg/ml of RNaseA in PBS 
and stained 5min with 25µg/ml of propidium iodide. Flow cytometry was 
performed with a FACScalibur flow cytometer (BD Biosciences). Analysis was 
performed using the CellQuest software.  
BrdU incorporation 
To examine growth arrest, cells were treated with 10 µM BrdU for 1 hr. Cells 
were then fixed in 4% paraformaldehyde, and costained with the anti-BrdU 
antibody and DAPI. Cells were then visualized with a fluorescent microscope. 
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Cell-based Ubiquitination Assay 
Cell-based ubiquitination assays were performed essentially as described [105] 
with some modifitions. H1299 cells were transfected with FLAG-Tip60, HA-
UHRF1 and His-ubiquitin. 24 hr post transfection, 10% of the cells were lysed 
with FLAG lysis buffer and extracts were saved as input. The rest of the cells 
were lysed with phosphate/guanidine buffer (6M guanidin-HCl, 0.1M Na2HPO4, 
6.8mM NaH2PO4, 10mM TrisHCl, pH8.0, 0.2% Triton-X100, freshly 
supplemented with 10mM β-mercaptoethanol and 5mM imidazole) with mild 
sonication and subjected to Ni-NTA (Qiagen) pulldown overnight. Ni-NTA 
captured fractions were then washed with phosphate/guanidine buffer and urea 
wash buffer (8M urea, 0.1M Na2HPO4, 6.8mM NaH2PO4, 10mM Tris-HCl, 
pH8.0, 0.2% Triton-X100, freshly supplemented with 10mM β-mercaptoethanol 
and 5mM imidazole) once each, and further washed 3 times with buffer (8M urea, 
18mM Na2HPO4, 80mM NaH2PO4, 10mM TrisHCl, pH6.3, 0.2% Triton-X100, 
freshly supplemented with 10mM β-mercaptoethanol and 5mM imidazole). 
Precipitates were eluted by 30 min incubation with Elution buffer (0.5M 
imidazole, 0.125M DTT) and resolved by SDS-PAGE. 
RNA Isolation and Quantitative RT-PCR 
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Total RNA was isolated from cells using TRIzol (Invitrogen) and treated with 
DNase I (Ambion). 2µg of total RNA was reverse-transcribed using SuperScript 
III First-Strand Synthesis Supermix (Invitrogen) and random primers following 
the manufacturer’s protocol. PCR was performed in triplicates using SYBR green 
mix (Applied Biosystems) with a 7500 Fast Real Time PCR System (Applied 
Biosystems). The relative amount of specific mRNA was first normalized to β-
actin and then to control sample (ctl RNAi, 0 hr).  
For the qRT-PCR analysis of human transcripts the following primers were 
used: HDM2 forward 5’-CGATGAATCTACAGGGACGCCATCG-3’,  
HDM2 reverse 5’-TCCTGATCCAACCAATCACCTG-3’;  
p21 forward 5’-CCATGTGGACCTGTCACTGTCTT-3’,  
p21 reverse 5’-CGGCCTCTTGGAGAAGATCAGCCG-3’;  
PUMA forward 5’-GGTCCTCAGCCCTCGCTCTC-3’,  
PUMA reverse 5’-GTACGACTTGTCTCCGCCGCTCGTAC-3’. 
GST-Pulldown Assay 
GST and GST-tagged protein fragments were purified as described previously 
[236]. 
35
S-methione labeled proteins were prepared by in vitro translation using 
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the TNT Coupled Reticulocyte Lysate System (Promega). GST or GST-tagged 
fusion proteins were incubated with in vitro translated 
35
S-methione-labeled 
proteins overnight at 4 °C in BC100 buffer containing 0.2% Triton X-100 and 0.2% 
BSA. GST resins (Novagen) were then added, and the solution was incubated at 
4 °C for 3 h. After five washes, the bound proteins were eluted for 1.5 hr at 4 °C 
in BC100 buffer containing 0.2% Triton X-100 and 20mM reduced glutathione 
(Sigma), and resolved by SDS-PAGE. The presence of 
35
S-labeled protein was 
detected by autoradiography. 
Immunofluorescent Staining 
Cells were washed with lukewarm phosphate buffered saline solution (PBS), 
and fixed with 4% paraformaldehyde in PBS at 37 °C for 30 min, rehydrated for 5 
min in serum-free DMEM, and permeabilized with 0.1% Triton X-100 in PBS for 
10 min at room temperature. Cells were incubated in blocking buffer (1% bovine 
serum albumin (BSA), 5% goat serum in PBS) for 45 min. Primary antibodies (as 
indicated) were added in blocking buffer for 1 hr at room temperature. After three 
washes with 1% BSA/PBS, Alexa Fluor conjugated secondary antibodies were 
added and incubated for 30 min at room temperature. Finally, cells were 














The critical role of p53 in tumor suppression is underscored by the high 
mutation rate of the Tp53 gene or the inactivation of the p53 regulatory pathway 
in human cancers. As a central coordinator of cellular responses to various stress 
types, p53 represses the propagation of damaged cells by transcription activation 
of specific target gene sets that transmit to the appropriate responses, including 
cell cycle arrest, apoptosis, cellular senescence, DNA repair, energy metabolism, 
and autophagy. The mechanisms defining which specific target gene sets are 
activated and which cellular outcomes are adopted upon p53 activation are not 
fully understood. This ignorance hampers the development of therapies that could 
employ the apoptotic potential of p53 for the selective elimination of cancer cells.  
Interestingly, the recently identified evolutionarily conserved acetylation site 
within the central DNA binding domain of p53 plays a key role in the selective 
activation of pro-apoptotic target genes and the apoptotic cell fate. Following 
acute DNA damage, as is often the case with chemotherapy and radiotherapy, 
Lys120 undergoes rapid acetylation mediated by the TIP60 acetyltransferase. 
Abrogation of this modification alone, as seen in the tumor-derived Arginine (R) 
mutant, completely abolishes the p53-dependent apoptotic response but retains the 
capactity to induce transient or permanent growth arrest. Although K120 
acetylation is indispensable for p53-dependnet apoptosis in vivo, the levels of 
K120 acetylation are dynamically regulated and the interaction between p53 and 
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TIP60 is quite unstable, indicating that additional regulators may play a role in 
controlling K120 acetylation and subsequent p53-mediated apoptotic response 
[225-227]. 
The identification of p90 and UHRF1 in this study as novel regulators of the 
TIP60-p53 interplay and TIP60-mediated p53 acetylation shed light on our 
understanding of how p53 acetylation at the K120 key site is achieved, and also 
provide insight on the regulation of the p53-mediated apoptotic response.  
4.1 p90 and renal cell carcinoma 
The differential effect of p90 on p53-mediated cell cycle arrest and apoptosis 
is of particular interest because it suggests that the level of cellular p90 could 
dictate the successful elimination of cancer cells through chemo- and/or 
radiotherapy induced apoptosis in wild type p53 retaining cancers. Importantly, 
p90 is one of several candidate tumor suppressor genes identified to be 
epigenetically inactivated in more than 30% of primary renal cell carcinomas 
(RCC) using the technique of methylated DNA immunoprecipitation (MeDIP) 
combined with high-density whole-genome microarray analysis [230]. 
Inactivation of p90 through RNAi also conferred anchorage-independent growth 
advantage in the kidney cancer derived HEK293 cells, dubbing p90 as a potential 
tumor suppressor whose inactivation may play in a role in kidney tumorigenesis. 
Interestingly, RCC is one of several tumor types that is highly resistant to chemo- 
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and radiotherapy, probably because RCC commonly retains wild type yet 
functionally inactive p53 [298]. In fact, in response to genotoxic stress, p53 
showed intact protein stabilization, nuclear translocation, and specific DNA 
binding in RCC [299], but fail to activate transcription. Functional and expression 
analysis of well known and commonly inactivated p53 regulators reveal that the 
observed defects of p53 function in RCC are not attributed to HDM2, HDMX or 
ARF mutation and/or inactivation. This suggests that the repression of p53 
transcription activation and the lack of apoptotic response to therapies in RCC are 
probably conferred through a less well-characterized p53 regulator.  
Future investigations are needed to elucidate if inactivation of p90 in RCC 
contributes, at least in part, to the repression of therapy induced p53-dependent 
apoptosis. Efforts should also be directed at reactivating p90 in RCC and 
determining if this may sensitize wild type p53-bearing tumors to chemo- and/or 
radiotherapies, although the selective reactivation of specific genes without 
impacting the global chromatin structure and epigenetic profile remains to be a 
major challenge.  
4.2 p90 and post-translational modifications 
p90 contains two sites (Ser 199 and Ser 302) (Fig. 5B) that can be potentially 
modified by the ATM/ATR DNA damage checkpoint protein kinases. ATM/ATR 
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substrates often contain serine or thereonine residues with glutamine (Q) at the +1 
position (the SQ/TQ motif) and immediately preceded by a hydrophobic or 
negatively charged amino acid [300]. In a large-scale proteomic screen assay 
performed by the Elledge Group utilizing SQ/TQ peptide immunoprecipitation, 
phosphorylated S302 peptide derived from p90 was identified as an ATM/ATR 
substrate [234].  Future efforts are needed to develop phospho-specific antibodies 
to p90 and validate if p90 undergoes DNA damage induced phosphorylation 
mediated by the ATRM/ATR kinases. Further investigations are also required to 
dissect whether p90 phosphorylation plays a modulating role on the p90-p53 
interaction, the p90-TIP60-p53 ternary complex formation, or the p53-mediated 
apoptotic response. It is possible that following DNA damage ATM/ATR 
mediated phosphorylation functionally regulates p90 to control the decision 
between cell cycle arrest and apoptosis mediated by p53.  
Bioinformatic analysis of p90 reveals a number of additional sites that are 
potentially modified through amidation, glycosylation, phosphorylation, and 
myristalation [301]. The specific enzymes catalyzing these modifications and 
their potential functional roles in regulating the p90-p53 interplay remain to be 
understood.  
4.3 p90 as a potential promoter specific cofactor for p53 
146 
 
Given that p90, TIP60 and p53 can form a ternary protein complex, whether 
this complex exists on chromatin is an interesting question. In the absence of 
TIP60 recruitment and histone H4 acetylation, transcription activation is limited 
to the HDM2 feedback target. When TIP60 is recruited to p53 responsive gene 
promoters and acetylates histone H4 in the vicinity of the promoter, transcription 
activation of growth arrest targets such as p21 is enabled; however the full 
activation of p53 transcription activity and the induction of apoptotic targets such 
as PUMA require not only histone H4 acetylation but also p53 K120 acetylation 
mediated by TIP60. It is possible that p90 coexists with TIP60 and p53 at 
apoptotic target promoters, facilitates K120 acetylation, and serve as a 
transcription coactivator. Although owing to antibody limitation, we did not 
detect co-recruitment of p90 at the PUMA promoter, this is an interesting 
hypothesis that should be further tested should a ChIP quality antibody for p90 
becomes available.  
4.4 The regulation of TIP60 
Downregulation of TIP60 expression has been observed in colon and lung 
cancers [302], and the HTATIP gene encoding TIP60 is a frequent target of mono-
allelic loss in human carcinomas, including lymphomas, head-and-neck 
carcinomas and mammary carcinomas [282]. Because TIP60 can broadly regulate 
transcription, DNA damage repair, growth arrest and apoptosis, TIP60 
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acetyltransferase activity should require tight regulation, since even a 2-fold 
reduction of its activity would result in accelerated lymphomagenesis driven by 
Myc activation [282] and excessive activation of TIP60 would result in apoptosis 
[303].  
Several studies have demonstrated that TIP60 activity is regulated by 
acetylation and phosphorylation. The autoacetylation of TIP60, which is 
augmented by UV radiation and negatively regulated by SIRT1, activates TIP60 
HAT activity through facilitating the dissociation of TIP60 oligomers and 
enhancing substrate binding [227]. The glycogen synthase kinase-3 (GSK-3) 
phosphorylates TIP60 at S86, and S86 phosphorylation of Tip60 is required for 
TIP60-mediated acetylation of p53 at K120, histone H4 acetylation at the PUMA 
promoter, and the induction of PUMA but not p21 transcription [283]. A recent 
study identified that TIP60 is phosphorlated at Y44 by the c-Abl proto-oncogene 
in response to damage, and Y44 phosphorylation of TIP60 triggers its 
acetyltransferase activity towards ATM [304]. c-Abl was previously shown to 
modulate p53 functions through phosphorylating HDM2 and impairing the 
inhibition of p53 by HDM2 [305,306]. It would be interesting to test if p53 
acetylation by TIP60 is also dependent on Y44 phosphorylation by c-Abl, as this 
would add another layer of regulation to p53 activation by c-Abl.    
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The identification of UHRF1 as a p53 regulator upstream of TIP60 also 
broadens our understanding of TIP60 regulation through ubiquitination. UHRF1 
targets TIP60 ubiquitination through atypical ubiquitin lysine linkages and TIP60 
ubiquitination mediated by UHRF1 does not promote protein turnover; 
nevertheless, the ubiquitinated form of TIP60 partially loses its acetyltransferase 
activity. Interestingly, two recent studies implicate that the USP7 deubiquitinase 
targets both UHRF1 and TIP60 for removal of ubiquitin chains [252,307]. Given 
that UHRF1 inhibits TIP60 function through both ubiquitination and direct 
impairment of the TIP60-p53 interaction, future investigations are required to 
determine the conditions that favor UHRF1 or TIP60 deubiquitination by USP7. It 
is likely that the modulation of the UHRF1-TIP60 interplay by USP7 is complex 
and non-linear, as in the case with USP7 modulation of HDM2/HDMX and p53.  
4.5 UHRF1 and cancer therapy 
UHRF1 expression is virtually non-detectable in terminally differentiated 
tissues, but detected exclusively in actively proliferating and/or undifferentiated 
cells and tissues, such as hematopoietic stem cells, germinal center B cells, and 
endometrial lining of the uterus [256,297,308,309]. UHRF1 expression is 
downregulated accompanied by differentiation [256,264,308,310]. 
Overexpression of UHRF1 is found in a wide array of human tumors, including 
breast cancer, pancreatic cancer, brain tumor, lung cancer, bladder and kidney 
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cancer, cervical cancer, and colon cancer [263,265-267,269-271], and the extent 
of UHRF1 overexpression has been linked to tumor progression and poor 
prognosis [270,277,278].  
The oncogenic role of UHRF1 has traditionally been attributed solely to its 
function in causing heterochromatin formation and transcription repression at 
promoters of certain tumor suppressor genes, including CDKN2A (encoding 
p16
INK4A
) [311], Human Mutant L homologue 1 (hMLH1) [312], Breast Cancer 
Eearly Onset (BRCA1) [313] and Retinoblastoma 1 (RB1 encoding pRB) [314]. 
The current study adds another layer to the oncogenic role of UHRF1: UHRF1 
promotes tumorigenesis and/or tumor progression through inhibition of the 
TIP60-p53 interplay and p53-dependent damage-induced apoptosis and growth 
arrest.  Future efforts are needed to investigate whether UHRF1 overexpression 
and p53 mutation are mutually exclusive in human tumors, identify wild type p53 
retaining tumors in which UHRF1 is upregulated, and test in these tumors 
whether downregulation of UHRF1 or treatment with small molecule inhibitors 
targeting UHRF1-TIP60 interaction would de-repress the TIP60-p53 interplay and 
reactivate p53-dependent growth arrest and apoptosis, thereby inhibiting tumor 
growth.   
Unlike genetic mutations which are irreversible, epigenetic alterations are 
reversible and sensitive to environmental conditions including nutritional changes 
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[315,316], making them interesting therapeutic targets.  To date two large families 
of specific inhibitors have been developed to target DNMT1 and HDAC1 [290], 
key partners of UHRF1 and components of the epigenetic regulating complex that 
are also upregulated in cancer [255,291-293,295]. For instance, the HDAC 
inhibitor Vorinostat (Zolinza
TM
, Merck, NJ) received approval by the US Food 
and Drug Administration (FDA) in 2006 and have shown efficacy for treatment of 
cutaneous T-cell lymphoma (CTCL) [290]; several other HDAC inhibitors are in 
clinical trial and  may follow soon. However the presence of 11 classical members 
of the HDAC family and the basal expression of HDACs in normal cells and 
tissues create significant challenge for high specificity: the currently available 
HDAC inhibitors target all or at least several of the 11 classical HDAC family 
members [291,296]. Cytosine analogues are another type of chemotherapeutic 
drugs targeting the UHRF1 complex. They work through occupying the cytosine 
recognition pocket of DNMT1, thereby inhibiting DNMT1 activity and promoting 
proteasome degradation [255]. Two such commercially available DNMT1 
inhibitors are azacitidine (Vidaza
TM
, Phamion, CO) and decitabine (Dacogen
TM
, 
SuperGen, CA, and MGI Pharma, MN). However because DNMT1 is 
ubiquitously expressed, including in vital organs such as the heart and kidney, 
cytosine analogues causes various adverse reactions and impose risks for causing 
genome-wide hypomethylation that contributes to further aggravation of cancer 
[255].   
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Considering that UHRF1 is required for DNMT1 and HDAC1 to fully exert 
their effects, and that UHRF1 has the additional function of suppressing the 
TIP60-p53 interplay, inhibition of UHRF1 would theoretically not only mimic the 
cumulative effects of HDAC1 and DNMT1 inhibitors, but also reactivate the p53 
pathway to achieve killing of cancer cells. Furthermore, in contrast to HDAC1 
and DNMT1, the basal expression of UHRF1 is almost non-detectable in normal 
tissues [255,297] and no expression of UHRF1 is observed at the protein level in 
vital organs including heart, lungs, liver, kidneys, and bladder [270]. This offers a 
foreseeable advantage that UHRF1 inhibitors may display a higher selectivity for 
tumor cells and have fewer side effects than currently available drugs targeting 
HDAC1 or DNMT1. One of the potential strategies for interfering with UHRF1-
TIP60 binding would be the utilization of a permeable dominant negative peptide 
that is a partial region of UHRF1 or TIP60 in their respective binding motifs. 
Similar approaches have proven successful in the treatment of breast cancer: a 
peptide derived from AMAP1 specifically blocked AMAP1-cortactin binding and 
effectively inhibited breast cancer invasion and metastasis [317].  
4.6 Acetylation is required for all major steps of p53 activation 
Based on current knowledge of p53 research reviewed in this thesis and the 
results in this study, we propose that the key steps in p53 transcription activity are 
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sequence specific DNA binding, de-repression from its key inhibitor HDM2, and 
promoter specific recruitment of corepressors/coactivators.  
Importantly acetylation is required for all the major steps of p53 activation: (i) 
p53 acetylation at the C-terminus enhances sequence-specific binding to DNA at 
target gene promoters [318]; (ii) C-terminal and K164 acetylation disrupts the 
repressive HDM2-p53-DNA complex on chromatin; and (iii) K120 acetylation is 
required for the full induction of transcription activity of p53 on pro-apoptotic 
targets and acetylated p53 recruits additional cofactors that are required for 
promoter specific transcription activation.   
The importance of p53 cofactors in regulating target specificity has been 
implicated by several studies. For example, the ankyrin-repeat, SH3-domain- and 
proline-rich-region-containing proteins (ASPP) family, consisting of two pro-
apoptotic mediators (ASPP1 and ASPP2) and one anti-apoptotic mediator iASPP, 
specifically regulates the p53-mediated apoptotic response.  ASPP1 and ASPP2 
selectively stimulates the apoptotic function of p53 by enhancing p53 binding to 
BAX, PUMA and PIG3 promoters [319], whereas iASPP counteracts the effects of 
ASPP1 and ASPP2 and inhibits p53-mediated apoptosis [320]. Interestingly the 
expression ratio of ASPP1/2 to iASPP correlates with the cellular sensitivity to 
apoptosis-inducing drugs [320]. In contrast, the hematopoietic zinc finger (HZF) 
protein, through direct interaction with the p53 DNA binding domain, enhances 
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p53 binding to p21 and 14-3-3σ promoters and attenuates PUMA and BAX 
expression, thereby favoring the pro-survival cell fate [321].  This current study 
identifying p90 to be another cofactor of p53 that stimulates TIP60-dependent 
acetylation at K120 and is specifically required for p53-mediated apoptosis 
broadens our knowledge of p53 cofactors and supports the importance of 




Figure 34. Three-step activation of p53 transcriptional activity  
p53 transcriptional activity is activated through three sequential steps: (i) 
sequence-specific DNA binding; (ii) anti-repression; and (iii) cofactor recruitment. 
Under homeostasis, p53 is bound to target gene promoter DNA but is repressed 
by Hdm2 and HdmX. Cellular stress triggers phosphorylation and acetylation at 
key p53 residues and facilitates the release of p53 from Hdm2 and HdmX 
mediated repression. The exact combinations of cofactors and post-translational 
modifications present on p53 provide promoter specificity. Anti-repression alone 
is sufficient for the induction of the p53 negative feedback loop. Cell cycle 
control requires partial activation of p53 through further modifications. Apoptotic 
activation requires the full activation of p53 activity via specific cofactors and an 
array of modifications. The control of p53 transcriptional regulation of 
metabolism and autophagy remains to be understood. Important p53 target genes 
for each cellular outcome are listed on the right. Abbreviations: TFs, transcription 






4.7 Other modifications/cofactors for p53 regulation of metabolism, 
antioxidant defense and autophagy 
It is noteworthy that although the best studied function of p53 is its control of 
temporary and permanent growth arrest and apoptotic cell death, ever-increasing 
evidence demonstrates that p53 regulates cellular metabolism, antioxidant defense, 
and autophagy [322-326]. A complete review of p53 regulation of target genes 
involved in these processes is beyond the scope of this thesis; instead, a few 
examples would be visited briefly.  
Cancer cells adopt a fundamentally different metabolic profile to sustain their 
rapid growth and survival in the stressful and dynamic microenvironment of the 
solid tumor [327]. One of the best characterized metabolic phenotypes of cancer 
cells is the “Warburg effect”, which describes the shift of energy generation from 
oxidative phosphorylation to aerobic glycolysis [328]. In normal cells, incoming 
glucose is converted through glycolysis to pyruvate, which then enters the 
mitochondrial tricarboxylic acid (TCA) cycle for maximal ATP generation 
through oxidative phosphorylation. Cancer cells, however, convert most of the 
incoming glucose to lactate even when oxygen is plentiful (thus termed “aerobic 
glycolysis”); this provides a high flux of biosynthetic substrates for 
macromolecule building, therefore offering a biosynthetic advantage to cancer 
cells [327]. Because ATP generation from aerobic glycolysis is less efficient in 
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terms of molecule of ATP generated per unit of glucose consumed, this must be 
compensated by a higher rate of glycolysis. Indeed cancer cells demand a 
significantly higher rate of glucose uptake and proliferating cancer cells typically 
have glycolytic rates up to 200 times higher than cells derived from their normal 
tissue of origin.  
p53 is known to downregulate glucose metabolism via transcription of the 
TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) [324]. TIGAR is an 
inhibitor of fructose-2,6-bisphosphate (Fru-2,6-P2), which strongly stimulates 
glycolysis at the third step of glucose breakdown through allosteric modulation of 
phosphofructokinase 1 (PFK-1) [329].  TIGAR directs glucose metabolism away 
from glycolysis and towards the pentose phosphate shunt, generating maximal 
levels of NADPH thus causing an increase in cellular glutathione (GSH), which 
acts as Reactive Oxygen Species (ROS) scavengers. ROS quenching protects the 
cell from p53-mediated apoptosis as a result of genotoxic stress [324]. 
Furthermore, increased NADPH inhibits apoptotic effector caspases, thus also 
contributing to the neutralization of the p53 apoptotic response [329].  
Glutaminase 2 (GLS2) is a p53 transcription target that plays important roles 
in the antioxidant defense mechanism. As a key enzyme in the conversion of 
glutamine to glutamate [326,330], GLS2 facilitates glutamine metabolism and 
synthesis of the glutathione antioxidant, thus lowering the levels of intracellular 
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ROS and decreasing overall DNA oxidation. By transcriptionally activating GLS2, 
p53 fights intracellular ROS, and prevents the accumulation of genomic damage, 
allowing cell survival after mild and repairable genotoxic stress [326].  
Autophagy allows recycling of intracellular constituents as an alternative 
energy source during periods of metabolic stress, thereby enabling homeostasis 
and viability [331]. Nuclear p53 induces autophagy following genotoxic stress by 
transcriptionally upregulating the mammalian Target Of Rapamycin (mTOR) 
inhibitors, Phosphatase and Tensin homolog (PTEN) and Tuberous Sclerosis 1 
(TSC1), or the p53-regulated autophagy and cell death gene Damage-Regulated 
Autophagy Modulator (DRAM) [323,325], whereas basal levels of cytoplasmic 
p53 inhibit autophagy through transcription-independent mechanisms such as 
AMP-Activated 10 Protein Kinase (AMPK) activation and mTOR inhibition 
[138,325,332].  
Interestingly, although loss of acetylation abolished p53-mediated 
transcription of canonical target genes involved in cell cycle arrest, apoptosis and 
senescence, the activation of metabolic and antioxidant defense targets such as 
TIGAR and GLS2 is retained by the p53
3KR
 mice [98], likely contributing to the 
suppression of early onset spontaneous tumorigenesis. Because the role of p53 in 
regulating metabolism, antioxidant defense and autophagy has only recently 
begun to be appreciated, in vitro and in vivo studies of p53 post-translational 
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modifications and their mediators have generally overlooked these aspects of p53 
function. Future efforts are required to further elucidate the exact combinations of 
post-translational modifications and the cofactors recruited for the transcription 
activation of such targets. Furthermore, previously generated p53 mutant mice 
and any future mouse models should also be carefully investigated for p53 
transcription dependent and -independent functions on metabolism, antioxidant 
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